US20210322571A1 - Aav vector for treatment of friedreich's ataxia - Google Patents
Aav vector for treatment of friedreich's ataxia Download PDFInfo
- Publication number
- US20210322571A1 US20210322571A1 US17/365,845 US202117365845A US2021322571A1 US 20210322571 A1 US20210322571 A1 US 20210322571A1 US 202117365845 A US202117365845 A US 202117365845A US 2021322571 A1 US2021322571 A1 US 2021322571A1
- Authority
- US
- United States
- Prior art keywords
- fxn
- promoter
- nucleic acid
- raav
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024412 Friedreich ataxia Diseases 0.000 title claims abstract description 23
- 239000013598 vector Substances 0.000 title description 54
- 238000011282 treatment Methods 0.000 title description 11
- 239000002245 particle Substances 0.000 claims abstract description 128
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 91
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 91
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 89
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 46
- 108091026890 Coding region Proteins 0.000 claims abstract description 30
- 108090000217 Frataxin Proteins 0.000 claims description 134
- 102000003869 Frataxin Human genes 0.000 claims description 132
- 230000014509 gene expression Effects 0.000 claims description 60
- 241000702421 Dependoparvovirus Species 0.000 claims description 40
- 238000002347 injection Methods 0.000 claims description 28
- 239000007924 injection Substances 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 23
- 238000010253 intravenous injection Methods 0.000 claims description 17
- 238000007913 intrathecal administration Methods 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 7
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract description 26
- 230000003612 virological effect Effects 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 58
- 108090000623 proteins and genes Proteins 0.000 description 41
- 239000013612 plasmid Substances 0.000 description 40
- 108010044052 Desmin Proteins 0.000 description 28
- 102100036912 Desmin Human genes 0.000 description 27
- 210000005045 desmin Anatomy 0.000 description 27
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000000234 capsid Anatomy 0.000 description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102000009836 Aconitate hydratase Human genes 0.000 description 10
- 108010009924 Aconitate hydratase Proteins 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 9
- 210000004413 cardiac myocyte Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 210000005260 human cell Anatomy 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108091035710 E-box Proteins 0.000 description 6
- 101150103820 Fxn gene Proteins 0.000 description 6
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 6
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 210000004153 islets of langerhan Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002438 mitochondrial effect Effects 0.000 description 6
- 210000005155 neural progenitor cell Anatomy 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- -1 AAV nucleic acid Chemical class 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 101000928044 Homo sapiens Desmin Proteins 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000012384 transportation and delivery Methods 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101100456626 Homo sapiens MEF2A gene Proteins 0.000 description 4
- 101100079042 Mus musculus Myef2 gene Proteins 0.000 description 4
- 102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- 108091036066 Three prime untranslated region Proteins 0.000 description 4
- 108091023045 Untranslated Region Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 101150014102 mef-2 gene Proteins 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 101150066583 rep gene Proteins 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101150044789 Cap gene Proteins 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 3
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- BKWBIMSGEOYWCJ-UHFFFAOYSA-L iron;iron(2+);sulfanide Chemical compound [SH-].[SH-].[Fe].[Fe+2] BKWBIMSGEOYWCJ-UHFFFAOYSA-L 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000013608 rAAV vector Substances 0.000 description 3
- 239000013646 rAAV2 vector Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 2
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000282709 Aotus trivirgatus Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010071200 Carbohydrate intolerance Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008072 Cerebellar syndrome Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000862448 Chlorocebus Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101150066038 E4 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005622 Gait Ataxia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101100120617 Homo sapiens FXN gene Proteins 0.000 description 1
- 206010021089 Hyporeflexia Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- SMNPLAKEGAEPJD-UHFFFAOYSA-N chembl34922 Chemical compound Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C=C4N=C(NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 SMNPLAKEGAEPJD-UHFFFAOYSA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000003703 cisterna magna Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SSJJWVREPZVNBF-DGXVIIAXSA-N dG10 Chemical compound C1=NC(C(NC(N)=N2)=O)=C2N1[C@H](O[C@@H]1COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C[C@@H]1OP(O)(=O)OC[C@@H](O1)[C@@H](O)C[C@@H]1N1C(N=C(NC2=O)N)=C2N=C1 SSJJWVREPZVNBF-DGXVIIAXSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 208000018904 loss of tendon reflex Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Definitions
- Friedreich's ataxia is a genetic disease that causes damage to the nervous system, resulting in degeneration of the spinal cord and peripheral nerves. Friedreich's ataxia is caused by a mutation in the FXN gene that results in an expansion of an intronic GAA repeat, which leads to reduced expression of the mitochondrial protein frataxin. There is currently no approved cure for Friedreich's ataxia.
- aspects of the disclosure relate to nucleic acids, recombinant adeno-associated virus (rAAV) particles, compositions, and methods related to gene therapy for Friedreich's ataxia (FRDA).
- rAAV recombinant adeno-associated virus
- a rAAV nucleic acid vector was designed containing a codon-optimized human FXN gene with a truncated human FXN 3′ UTR, operably linked to a promoter.
- this vector was delivered in a rAAV particle to cardiomyocytes differentiated from induced pluripotent stem cells (IPSC) derived from FRDA, the cells had increased mitochondrial activity. This improvement in mitochondrial activity was correlated with increased levels of FXN expression in vitro. It is believed that this vector may be useful for treatment of FRDA.
- IPC induced pluripotent stem cells
- the disclosure provides a nucleic acid comprising an expression construct comprising a human frataxin (FXN) coding sequence and a truncated human FXN 3′ untranslated region (UTR) operably linked to a promoter (e.g., a Desmin promoter, a CBA promoter, a hFXNPro, or other suitable promoter), wherein the expression construct is flanked on each side by an inverted terminal repeat sequence (e.g., an AAV ITR).
- a promoter e.g., a Desmin promoter, a CBA promoter, a hFXNPro, or other suitable promoter
- an inverted terminal repeat sequence e.g., an AAV ITR
- the human FXN coding sequence is codon-optimized for expression in human cells.
- the FXN coding sequence comprises the sequence of SEQ ID NO: 1.
- the promoter comprises one or more of the following: a Desmin promoter, a chicken ⁇ -actin (CBA) promoter, or an endogenous human FXN promoter (hFXNPro), or a fragment or derivative of one or more thereof sufficient to drive expression of the FXN coding sequence (e.g., in human cells).
- the Desmin promoter comprises the sequence of SEQ ID NO: 2.
- the CBA promoter comprises the sequence of SEQ ID NO: 7.
- the hFXNPro comprises the sequence of SEQ ID NO: 8.
- the truncated human FXN 3′ UTR has the sequence of SEQ ID NO: 3.
- the expression construct comprises the sequence of SEQ ID NO: 4 (or a portion thereof comprising a gene of interest under the control of a promoter of interest, optionally flanked by ITR sequences).
- the nucleic acid is a recombinant adeno-associated virus (rAAV) vector.
- the nucleic acid is a single-stranded or self-complementary rAAV nucleic acid vector.
- the nucleic acid comprises an expression construct comprising a human frataxin (FXN) coding sequence and a truncated human FXN 3′ untranslated region (UTR) operably linked to a promoter (e.g., a Desmin promoter, a CBA promoter, a hFXNPro, or other suitable promoter), wherein the expression construct is flanked on each side by an inverted terminal repeat sequence.
- FXN human frataxin
- UTR truncated human FXN 3′ untranslated region
- the human FXN coding sequence is codon-optimized for expression in human cells.
- the FXN coding sequence comprises the sequence of SEQ ID NO: 1.
- the promoter comprises one or more of the following: a Desmin promoter, a chicken ⁇ -actin (CBA) promoter, or an endogenous human FXN promoter (hFXNPro), or a fragment or derivative of one or more thereof sufficient to drive expression of the FXN coding sequence (e.g., in human cells).
- the Desmin promoter comprises the sequence of SEQ ID NO: 2.
- the CBA promoter comprises the sequence of SEQ ID NO: 7.
- the hFXNPro comprises the sequence of SEQ ID NO: 8.
- the truncated human FXN 3′ UTR has the sequence of SEQ ID NO: 3.
- the expression construct comprises the sequence of SEQ ID NO: 4 (or a portion thereof comprising a gene of interest under the control of a promoter of interest, optionally flanked by ITR sequences).
- the nucleic acid is a recombinant adeno-associated virus (rAAV) vector.
- the nucleic acid is a single-stranded or self-complementary rAAV nucleic acid vector.
- the rAAV particle is an AAV9 particle.
- the disclosure relates to a composition comprising a plurality of an rAAV particle as described herein.
- the rAAV particle comprises a nucleic acid as described herein.
- the human FXN coding sequence is codon-optimized for expression in human cells.
- the FXN coding sequence comprises the sequence of SEQ ID NO: 1.
- the promoter comprises one or more of the following: a Desmin promoter, a chicken ⁇ -actin (CBA) promoter, or an endogenous human FXN promoter (hFXNPro), or a fragment or derivative of one or more thereof sufficient to drive expression of the FXN coding sequence (e.g., in human cells).
- the Desmin promoter comprises the sequence of SEQ ID NO: 2.
- the CBA promoter comprises the sequence of SEQ ID NO: 7.
- the hFXNPro comprises the sequence of SEQ ID NO: 8.
- the truncated human FXN 3′ UTR has the sequence of SEQ ID NO: 3.
- the expression construct comprises the sequence of SEQ ID NO: 4 (or a portion thereof comprising a gene of interest under the control of a promoter of interest, optionally flanked by ITR sequences).
- the nucleic acid is a recombinant adeno-associated virus (rAAV) vector.
- the nucleic acid is a single-stranded or self-complementary rAAV nucleic acid vector.
- the rAAV particle is an AAV9 particle (e.g., the rAAV particle comprises viral capsid proteins of serotype 9).
- the composition further comprises a pharmaceutically acceptable carrier.
- the disclosure provides a method of treating Friedreich's ataxia, the method comprising administering a therapeutically effective amount of an rAAV particle as described above or as described elsewhere herein or a composition as described above or as described elsewhere herein to a subject having Friedreich's ataxia.
- the rAAV particle or composition are administered via intravenous injection.
- the rAAV particle or composition are administered via intrathecal injection.
- the rAAV particle or composition are administered via intracisternal injection.
- the rAAV particle or composition are administered via intravenous injection and intrathecal injection.
- the rAAV particle or composition are administered via intravenous injection and intracisternal injection.
- the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intrathecal injection is between 10:1 and 1:1 (e.g., around 5:1, or around 10:1). In some embodiments, the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intrathecal injection is between 1:1 and 1:10 (e.g., around 1:5, or around 1:10). In some embodiments, the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intracisternal injection is between 10:1 and 1:1 (e.g., around 5:1, or around 10:1). In some embodiments, the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intracisternal injection is between 1:1 and 1:10 (e.g., around 1:5, or around 1:10).
- FIG. 1 is a non-limiting plasmid map showing an expression construct containing a Desmin (DES) promoter, a codon-optimized human FXN coding sequence, and a truncated human FXN 3′ UTR, the expression construct flanked by inverted terminal repeat sequences (ITRs).
- DES Desmin
- ITRs inverted terminal repeat sequences
- FIG. 2A shows an exemplary photograph of renal epithelial cells (REC) isolated from FRDA patients.
- FIG. 2B shows an exemplary photograph of induced pluripotent stem cells (IPSCs) generated from the RECs.
- ISCs induced pluripotent stem cells
- FIG. 2C shows a photograph of a contracting cardiomyocyte generated from the IPSCs.
- FIG. 3A shows a series of exemplary photographs of cardiomyocytes generated from the IPSCs stained with different markers.
- (i) shows DAPI staining
- (ii) shows NKX2.5 staining
- (iii) shows TroponinT staining
- (iv) shows an overlay of (i)-(iii).
- FIG. 3B shows a series of exemplary photographs of neural progenitor cells (NPCs) generated from the IPSCs stained with different markers.
- NPCs neural progenitor cells
- FIG. 4 shows an image of an exemplary Western blot stained with an anti-frataxin antibody.
- “+” is FA2 cells transiently transfected with the FXN expression plasmid.
- “ ⁇ ” is FA2 cells that are not transfected. 1 ug, 5 ug, and 10 ug are amounts of purified FXN.
- FIG. 5A shows exemplary aconitase activity in FRDA patient-derived cells.
- FA2 untreated FRDA cells
- FA2+FXN FRDA cells transiently transfected with the FXN expression plasmid
- CTRL Healthy control cells
- CTRL+FXN healthy control cells transiently transfected with the FXN expression plasmid.
- FIG. 5B shows exemplary aconitase activity in FRDA patient-derived cells.
- FA2 CTRL FRDA cell without transfection
- FA2 TX 1 ⁇ g FRDA cells transfected with 1 ⁇ g of plasmid
- FA2 TX 5 ⁇ g FRDA cells transfected with 5 ⁇ g of plasmid
- FA2 TX 10 ⁇ g FRDA cells transfected with 10 ⁇ g of plasmid.
- FIG. 6 shows an exemplary map of a Desmin promoter.
- FRDA Friedrich's ataxia
- TNR trinucleotide repeat expansion
- FXN frataxin
- FXN mitochondrial protein frataxin
- FRDA affects 1 in 50,000 people worldwide and is characterized by progressive neural degeneration, such as ataxia, sensory loss, muscle weakness, and hypertrophic cardiomyopathy. Symptoms generally present at puberty and patients have a shorter than normal life expectancy reaching 40-50 years of age.
- Frataxin is a highly conserved, 210 amino acid ( ⁇ 17 kDa) protein encoded in the nucleus. While frataxin's specific function remains unclear, homozygous deletions are embryonically lethal. Evidence suggests frataxin is involved in iron metabolism, iron storage, iron-sulfur cluster (ISC) formation, and protection against reactive oxygen species (ROS). Dysregulation of FXN leads to iron accumulation in the mitochondria and insufficient iron in the cytoplasm. Excess mitochondrial iron increases the incidence of iron-catalyzed reduction of hydrogen peroxide generating toxic ROS. The increase in ROS disrupts iron homeostasis in the mitochondria and affects the ISC aconitase, a major component of cellular respiration.
- ISC iron-sulfur cluster
- FRDA major neurological symptoms include muscle weakness and ataxia, a loss of balance and coordination.
- FRDA mostly affects the spinal cord and the peripheral nerves that connect the spinal cord to the body's muscles and sensory organs.
- FRDA affects the function of the cerebellum and also the musculature of the heart.
- FXN deficiency in pancreatic islet cells causes diabetes (Ristow, M, et al., J Clin Invest. 112(4): 527-534, 2003).
- the neurological degeneration in FRDA patients needs to be addressed.
- the cardiac disease in FRDA patients needs to be addressed.
- the fundamental principle is based on the ability to restore proper gene function in target tissues.
- nucleic acids, compositions and methods that can be used to achieve global gene transfer using AAV vectors, and that can target both the neurological and cardiac impairment in FRDA.
- “global” refers to an entire organ, system of the body (e.g., CNS) or body.
- the disclosed nucleic acids encoding FXN, compositions and methods which relate to both choice of promoter and routes of rAAV particle delivery to a subject, enable targeting multiple affected organs in a subject with FRDA, including cardiac muscle, pancreas (e.g., pancreatic islet cells), and/or CNS (e.g., dorsal root ganglia, and the cerebellum).
- a gene therapy strategy that increases frataxin levels may be useful to treat FRDA or one or more symptoms thereof.
- Adeno-associated viruses are among the most common vectors used in gene therapy due to persistent, robust gene expression, a lack of toxicity, and limited immune response.
- challenges in AAV-mediated neural delivery and targeting have yet to be fully characterized.
- a rAAV-FXN vector driven by a promoter sequence (e.g., a Desmin promoter) was developed and shown to be capable of increasing expression of frataxin and restoring mitochondrial function in cells from FRDA patients.
- rAAV Recombinant Adeno-Associated Virus
- a nucleic acid comprising an expression construct containing a FXN coding sequence (e.g., a human FXN coding sequence) linked to a promoter (e.g., a Desmin promoter, for example a human Desmin promoter, a CBA promoter, a hFXNPro, or other suitable promoter).
- a promoter e.g., a Desmin promoter, for example a human Desmin promoter, a CBA promoter, a hFXNPro, or other suitable promoter.
- the expression construct further contains a FXN 3′ untranslated region (UTR) that is 3′ to the FXN coding sequence.
- the expression construct is flanked on each side by an inverted terminal repeat sequence (e.g., an AAV ITR).
- Recombinant AAV (rAAV) nucleic acids are, herein, equivalent to rAAV nucleic acid vectors (e.g., a plasmid that is used to prepare a rAAV, a nucleic acid comprising a gene of interest and a promoter flanked by ITRs that are packaged in an rAAV particle, or other nucleic acid described herein that comprises or encodes a nucleic acid that is packaged in a rAAV, or that encodes one or more viral proteins).
- rAAV nucleic acids can be circular, linear, single-stranded, or double-stranded, depending on the context.
- a nucleic acid is an RNA molecule.
- a nucleic acid is a DNA molecule.
- recombinant AAV (rAAV) vectors can be nucleic acid vectors that are used to transfect cells in which the expression construct that is comprised by the vector is packaged (or encapsidated) into rAAV particles.
- rAAV vectors can be the nucleic acid flanked by ITRs (and including the ITRs) that is packaged in a rAAV.
- composition or nucleic acid described herein with reference to a particular sequence can be provided as a composition or nucleic acid (e.g., RNA or DNA) comprising a single-stranded nucleic acid having that sequence, or a composition or nucleic acid (e.g., RNA or DNA) comprising a single-stranded nucleic acid having the complement of that sequence, or a composition or nucleic acid (e.g., RNA or DNA) comprising a double-stranded nucleic acid one strand of which has that sequence, or a composition or nucleic acid (e.g., RNA or DNA) comprising a portion of one or more of such nucleic acids, or a combination thereof.
- a composition or nucleic acid e.g., RNA or DNA
- the FXN coding sequence encodes a human frataxin protein.
- An exemplary human frataxin protein is shown below:
- Exemplary human FXN protein (SEQ ID NO: 6) MWTLGRRAVAGLLASPSPAQAQTLTRVPRPAELAPLCGRRGLRTDIDATC TPRRASSNQRGLNQIWNVKKQSVYLMNLRKSGTLGHPGSLDETTYERLAE ETLDSLAEFFEDLADKPYTFEDYDVSFGSGVLTVKLGGDLGTYVINKQTP NKQIWLSSPSSGPKRYDWTGKNWVFSHDGVSLHELLAAELTKALKTKLDL SWLAYSGKDAIDIPSPVLRTLKAIRPRPQLHYAAEVCFLLLLLFIFFIPA FEDSWAMCHSSVERMCCLLPCPQVLIFNFYGRFFGLSDFLPHMIPLIFYN VLCLYLNITTFKKAK
- the FXN coding sequence is codon-optimized for expression in human cells, e.g., by adjusting codon usage within the coding sequence to codons commonly used by human cells.
- the FXN coding sequence is further optimized to remove extra GC content, ribosomal binding sites, consensus and cryptic splice sites, repeats, and/or secondary structures. Optimization of coding sequences (e.g., codon-optimization) can be accomplished using any method known in the art, e.g., using GeneOptimizer® software from LifeTechnologies.
- the codon-optimized human FXN coding sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence of SEQ ID NO: 1. In some embodiments, the codon-optimized human FXN coding sequence comprises the sequence of SEQ ID NO: 1.
- the promoter is a Desmin promoter, or a fragment or variant thereof that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or more of the activity (e.g., promotion of transcription of a gene, such as in a neuronal or muscle cell) of a wild-type human Desmin promoter.
- the promoter comprises two or more fragments of a Desmin promoter (e.g., an enhancer fragment and a basal promoter fragment, which may be fused together optionally with a spacer sequence).
- the fragment(s) may be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 200, 250, 500, 1000 or more nucleotides shorter than a wild-type human Desmin promoter.
- the Desmin promoter comprises one or more of (e.g., one, two, three, or four of) a MEF2 responsive element, a MyoD E-box, a CACC box and a TATA box.
- the promoter has a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence of SEQ ID NO: 2.
- the promoter is a Desmin promoter having the sequence of SEQ ID NO: 2.
- Desmin promoter sequence potential MEF2 responsive element (with 9 bp AT-rick core) at position 65-73, MyoD E-box at position 97-102, CACC box at position 160-163 (binds nuclear factors present in cardiac and skeletal muscle myocytes), CACC box at position 176-179, CACC box at position 179-182, CACC box at position 253-256, MyoD E-box at position 270-275, CACC box at position 338-341, MyoD E-box at position 542-547, TATA box at position 585-590, and CACC box at position 696-699).
- the promoter is a Chicken ⁇ -actin (CBA) promoter, or a fragment or variant thereof that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or more of the activity (e.g., promotion of transcription of a gene, such as in a neuronal or muscle cell) of a wild-type full-length promoter.
- the promoter comprises two or more fragments of a CBA promoter (e.g., an enhancer fragment and a basal promoter fragment, which may be fused together optionally with a spacer sequence).
- the fragment(s) may be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 200, 250, 500, 1000 or more nucleotides shorter than the full-length CBA promoter.
- the CBA promoter comprises one or more of (e.g., one, two, three, or four of) a MEF2 responsive element, a MyoD E-box, a CACC box and a TATA box.
- the promoter has a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence of SEQ ID NO: 7.
- the promoter is a CBA promoter having the sequence of SEQ ID NO: 7.
- Exemplary CBA promoter sequence (SEQ ID NO: 7) ctagatctgaattcggtaccctagttattaatagtaatcaattacggggt cattagttcatagcccatatatggagttccgcgttacataacttacggta aatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaat aatgacgtatgttcccatagtaacgccaatagggactttccattgacgtc aatgggtggactatttacggtaaactgcccacttggcagtacatcaagtg tatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggccccctattgacgtcaatgacggtaaatggccccctat
- the promoter is a human FXN promoter (hFXNPro promoter), or a fragment or variant thereof that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or more of the activity (e.g., promotion of transcription of a gene, such as in a neuronal or muscle cell) of a wild-type hFXNPro.
- the promoter comprises two or more fragments of a hFXNPro (e.g., an enhancer fragment and a basal promoter fragment, which may be fused together optionally with a spacer sequence).
- the fragment(s) may be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 200, 250, 500, 1000 or more nucleotides shorter than a wild-type hFXNPro.
- the hFXNPro comprises one or more of (e.g., one, two, three, or four of) a MEF2 responsive element, a MyoD E-box, a CACC box and a TATA box.
- the promoter has a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence of SEQ ID NO: 8.
- the promoter is a hFXNPro having the sequence of SEQ ID NO: 8.
- hFXNPro sequence (SEQ ID NO: 8) AAGAAAACTTTCACAATTTGCATCCCTTTGTAATATGTAACAGAAATAAA ATTCTCTTTTAAAATCTATCAACAATAGGCAAGGCACGGTGGCTCACGCC TGTCGTCTCAGCACTTTGTGAGGCCCAGGCGGGCAGATCGTTTGAGCCTA GAAGTTCAAGACCACCCTGGGCAACATAGCGAAACCCCCTTTCTACAAAA
- the promoter has a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence identified as nucleotides 2312-2404 of GenBank accession No. NC_001510.1.
- the FXN 3′ untranslated region is a truncated FXN 3′ UTR.
- the truncated FXN 3′ UTR is a truncated human FXN 3′ UTR.
- the truncated FXN 3′ UTR is at least 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000 or more nucleotides shorter than a wild-type FXN 3′ UTR.
- the 3′ UTR is truncated (e.g., by at least 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000 or more nucleotides) and the truncated sequence has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the corresponding sequence in a wild-type FXN 3′ UTR.
- the 3′ UTR is truncated relative to the below wild-type FXN 3′ UTR.
- the truncated 3′ UTR is no more than 2000, 1900, 1800, 1700, 1600, 1500, 1400, 1300, 1200, 1100, or 1000 nucleotides in length.
- Exemplary human FXN 3′ UTR (SEQ ID NO: 9) 1 ACTAGTGCCA CCATGTGGAC ACTGGGGAGA AGGGCCGTGG CTGGACTGCT GGCTTCTCCA 61 TCTCCAGCCC AGGCCCAGAC CCTGACCAGA GTGCCTAGAC CTGCCGAACT GGCCCCTCTG 121 TGTGGCAGAA GAGGCCTGAG AACCGACATC GACGCCACCT GTACCCCCAG AAGGGCCAGC 181 AGCAATCAGC GGGGCCTGAA TCAGATCTGG AACGTGAAGA AACAGAGCGT GTACCTGATG 241 AACCTGAGAA AGAGCGGCAC CCTGGGCCAC CCTGGAAGCC TGGATGAGAC AACCTACGAG 301 CGGCTGGCCG AGGAAACCCT GGATTCCCTG GCCGAGTTCT TCGAGGACCT GGCCGACAAG 361 CCCTACACCT TCGAGGATTA CGACGTGTCC TTCGGCAGCG
- the truncated FXN 3′ UTR has the sequence of SEQ ID NO: 3.
- Exemplary truncated FXN 3′ UTR (SEQ ID NO: 3) AAGAAGGAAAAATTCCAGGAGGGAAAATGAATTGTCTTCACTCTTCATTC TTTGAAGGATTTACTGCAAGAAGTACATGAAGAGCAGCTGGTCAACCTGC TCACTGTTCTATCTCCAAATGAGACACATTAAAGGGTAGCCTACAAATGT TTTCAGGCTTCTTTCAAAGTGTAAGCACTTCTGAGCTCTTTAGCATTGAA GTGTCGAAAGCAACTCACACGGGAAGATCATTTCTTATTTGTGCTCTGTG ACTGCCAAGGTGTGGCCTGCACTGGGTTGTCCAGGGAGACATGCATCTAG TGCTGTTTCTCCCACATATTCACATACGTGTCTGTGTGTATATATATTTT TTCAATTTAAAGGTTAGTATGGAATCAGCTGCTACAAGAATGCAAAAAAT CTTCCAAAGACAAGAAAAGAGGAAAAAAAAAAAAAAT CTTCCAAAGACAAGAAAAGAGGAAAAAAAAA
- the expression construct further contains a nucleic acid segment that encode a polyadenylation signal.
- the nucleic acid segment is positioned 3′ to the FXN 3′ UTR in the expression construct.
- the expression construct comprises the sequence of SEQ ID NO: 4 (or a portion thereof comprising a gene of interest under the control of a promoter of interest, optionally flanked by ITR sequences).
- the nucleic acid is a plasmid. In some embodiments, the nucleic acid comprises or consists of the sequence of SEQ ID NO 5.
- the nucleic acid is a recombinant adeno-associated virus (rAAV) vector.
- rAAV adeno-associated virus
- Exemplary rAAV nucleic acid vectors useful according to the disclosure include single-stranded (ss) or self-complementary (sc) AAV nucleic acid vectors.
- a recombinant rAAV particle comprises (or packages) a nucleic acid vector that comprises an expression construct, such as a single-stranded (ss) or self-complementary (sc) AAV nucleic acid vector.
- a nucleic acid vector that comprises an expression construct, such as a single-stranded (ss) or self-complementary (sc) AAV nucleic acid vector.
- the nucleic acid vector comprises an expression construct comprising FXN coding sequence (e.g., a human FXN coding sequence) and a truncated FXN 3′ UTR (e.g., a truncated human FXN 3′ UTR) operably linked to a promoter (e.g., a Desmin promoter, a CBA promoter, a hFXNPro, or other promoter) and is flanked by regions comprising inverted terminal repeat (ITR) sequences (e.g., wild-type ITR sequences or engineered ITR sequences).
- a promoter e.g., a Desmin promoter, a CBA promoter, a hFXNPro, or other promoter
- ITR inverted terminal repeat
- the nucleic acid is encapsidated by a viral capsid.
- a rAAV particle comprises a viral capsid and a nucleic acid vector as described herein, which is encapsidated by the viral capsid.
- the viral capsid comprises 60 capsid protein subunits comprising VP1, VP2 and VP3.
- the VP1, VP2, and VP3 subunits are present in the capsid at a ratio of approximately 1:1:10, respectively.
- the ITR sequences of a nucleic acid or nucleic acid vector described herein can be derived from any AAV serotype (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11,12, or 13) or can be derived from more than one serotype. In some embodiments of the nucleic acid or nucleic acid vector provided herein, the ITR sequences are derived from AAV2.
- ITR sequences and plasmids containing ITR sequences are known in the art and commercially available (see, e.g., products and services available from Vector Biolabs, Philadelphia, Pa.; Cellbiolabs, San Diego, Calif.; Agilent Technologies, Santa Clara, Calif.; and Addgene, Cambridge, Mass.; and Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.
- Kessler P D Podsakoff G M, Chen X, McQuiston S A, Colosi P C, Matelis L A, Kurtzman G J, Byrne B J. Proc Natl Acad Sci USA. 1996 Nov. 26; 93(24):14082-7; and Curtis A. Machida.
- the nucleic acid or nucleic acid vector comprises a pTR-UF-11 plasmid backbone, which is a plasmid that contains AAV2 ITRs, or a nucleic acid region of the pTR-UF-11 plasmid that comprises the ITRs.
- This plasmid is commercially available from the American Type Culture Collection (ATCC MBA-331).
- One or more genes of interest for example encoding a therapeutic protein
- a promoter of interest for example a Desmin promoter or derivative thereof described in this application
- a promoter of interest for example a Desmin promoter or derivative thereof described in this application
- These can be used as described in this application to produce a rAAV particle encapsidating a rAAV nucleic acid comprising ITRs flanking a gene of interest under the control of a promoter of interest.
- the expression construct is no more than 7 kilobases, no more than 6 kilobases, no more than 5 kilobases, no more than 4 kilobases, or no more than 3 kilobases in size. In some embodiments, the expression construct is between 4 and 7 kilobases in size.
- the expression construct comprises one or more regions comprising a sequence that facilitates expression of the FXN coding sequence, e.g., expression control sequences operably linked to the FXN coding sequence.
- expression control sequences include promoters, insulators, silencers, response elements, introns, enhancers, initiation sites, termination signals, and poly(A) tails. Any combination of such control sequences is contemplated herein (e.g., a promoter and an enhancer).
- the promoter is a Desmin promoter as described herein.
- the expression construct contains a splice donor/acceptor site, such as between the promoter and the FXN coding sequence.
- any of a number of promoters suitable for use in the selected host cell may be employed.
- the promoter may be, for example, a constitutive promoter, tissue-specific promoter, inducible promoter, or a synthetic promoter.
- constitutive promoters of different strengths can be used.
- a nucleic acid vector described herein may include one or more constitutive promoters, such as viral promoters or promoters from mammalian genes that are generally active in promoting transcription.
- constitutive viral promoters include the Herpes Simplex virus (HSV), thymidine kinase (TK), Rous Sarcoma Virus (RSV), Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV), Ad E1A and cytomegalovirus (CMV) promoters.
- Non-limiting examples of constitutive mammalian promoters include various housekeeping gene promoters, as exemplified by the ⁇ -actin promoter (e.g., chicken ⁇ -actin promoter) and human elongation factor-1 ⁇ (EF-1 ⁇ ) promoter.
- ⁇ -actin promoter e.g., chicken ⁇ -actin promoter
- EF-1 ⁇ human elongation factor-1 ⁇
- Inducible promoters and/or regulatory elements may also be contemplated for achieving appropriate expression levels of FXN.
- suitable inducible promoters include those from genes such as cytochrome P450 genes, heat shock protein genes, metallothionein genes, and hormone-inducible genes, such as the estrogen gene promoter.
- Another example of an inducible promoter is the tetVP16 promoter that is responsive to tetracycline.
- Tissue-specific promoters and/or regulatory elements are also contemplated herein.
- Non-limiting examples of such promoters that may be used include hematopoietic stem cell-specific promoters.
- a synthetic promoter may comprise, for example, regions of known promoters, regulatory elements, transcription factor binding sites, enhancer elements, repressor elements, and the like.
- the use of AAV has advanced in recent years, gene transfer still faces some obstacles.
- tissue specific targeting to deliver the gene to affected organs or to avoid toxicity remains a challenge.
- High levels of over-expression driven by a strong promoter can lead to toxicity in vitro.
- organ specificity of different promoters can be taken advantage of to achieve sufficient gene delivery to target organs while avoiding complications related to administration of high doses.
- identification of the most efficient and safe promoter element for the transcriptional control of the FXN transgene can be used to correct FXN deficiency in the heart, CNS and in the pancreatic islet cells.
- the promoter in the disclosed nucleic acid is a human Desmin promoter or a derivative thereof.
- the Desmin promoter is a tissue-restricted promoter for cardiac muscle and neurons.
- the Desmin promoter element is a derivative of the Desmin gene control element, which contains additional transcriptional control elements to augment expression.
- the promoter in the disclosed nucleic acid is the chicken ⁇ -actin (CBA) promoter.
- the CBA promoter is a constitutive element made up of the cytomegalovirus (CMV) immediate early enhancer element, the beta-actin promoter and globin intron.
- CBA promoter allows targeting of muscle, neurons and the pancreas for FXN transgene delivery.
- the promoter in the disclosed nucleic acid is the endogenous frataxin promoter (FxP), hFXNPro, which has been mapped to encompass a 1 kb region 5′ to the frataxin transcriptional start site. In some embodiments, the promoter in the disclosed nucleic acid is the endogenous frataxin promoter (FxP), hFXNPro, which has been mapped to encompass a 1.220 kb region 5′ to the frataxin transcriptional start site. In some embodiments, no remote enhancer elements are required, and all the necessary transcriptional control and tissue restricted activity are conferred by the frataxin promoter. However, additional regulatory sequences can be used in some embodiments.
- the CBA promoter and the hFXNPro allow targeting of the pancreatic islet cells for FXN gene delivery.
- the nucleic acid is a plasmid (e.g., a circular nucleic acid comprising one or more of an origin of replication, a selectable marker, and a reporter gene).
- a nucleic acid described herein, such as a plasmid may also contain marker or reporter genes, e.g., LacZ or a fluorescent protein, and an origin of replication.
- the plasmid is transfected into a producer cell that produces AAV particles containing the expression construct (e.g., the expression construct that was included in the plasmid that was used to produce the nucleic acid that was encapsidated by the rAAV particles).
- AAV particles containing the expression construct e.g., the expression construct that was included in the plasmid that was used to produce the nucleic acid that was encapsidated by the rAAV particles.
- the rAAV particle may be of any AAV serotype (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13), including any derivative (including non-naturally occurring variants of a serotype) or pseudotype.
- the rAAV particle is an AAV9 particle, which may be pseudotyped with AAV2 ITRs.
- Non-limiting examples of derivatives and pseudotypes include AAV2-AAV3 hybrid, AAVrh.10, AAVhu.14, AAV3a/3b, AAVrh32.33, AAV-HSC15, AAV-HSC17, AAVhu.37, AAVrh.8, CHt-P6, AAV2.5, AAV6.2, AAV2i8, AAV-HSC15/17, AAVM41, AAV9.45, AAV6(Y445F/Y731F), AAV2.5T, AAV-HAE1/2, AAV clone 32/83, AAVShH10, AAV2 (Y->F), AAV8 (Y733F), AAV2.15, AAV2.4, AAVM41, and AAVr3.45.
- the rAAV particle is a pseudotyped rAAV particle, which comprises (a) a nucleic acid vector comprising ITRs from one serotype (e.g., AAV2) and (b) a capsid comprised of capsid proteins derived from another serotype (e.g., AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10).
- a pseudotyped rAAV particle which comprises (a) a nucleic acid vector comprising ITRs from one serotype (e.g., AAV2) and (b) a capsid comprised of capsid proteins derived from another serotype (e.g., AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10).
- rAAV particles and nucleic acid vectors are also known in the art and commercially available (see, e.g., Zolotukhin et al., Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167; and U.S. Patent Publication Numbers US20070015238 and US20120322861, which are incorporated herein by reference; and plasmids and kits available from ATCC and Cell Biolabs, Inc.).
- the nucleic acid vector (e.g., as a plasmid) may be combined with one or more helper plasmids, e.g., that contain a rep gene (e.g., encoding Rep78, Rep68, Rep52 and Rep40) and a cap gene (encoding VP1, VP2, and VP3), and transfected into a producer cell line such that the rAAV particle can be packaged and subsequently purified.
- helper plasmids e.g., that contain a rep gene (e.g., encoding Rep78, Rep68, Rep52 and Rep40) and a cap gene (encoding VP1, VP2, and VP3)
- the packaging is performed in a helper cell or producer cell, such as a mammalian cell or an insect cell.
- a helper cell or producer cell such as a mammalian cell or an insect cell.
- mammalian cells include, but are not limited to, HEK293 cells, COS cells, HeLa cells, BHK cells, or CHO cells (see, e.g., ATCC® CRL-1573TM, ATCC® CRL-1651TM, ATCC® CRL-1650TM, ATCC® CCL-2, ATCC® CCL-10TM, or ATCC® CCL-61TM).
- Exemplary insect cells include, but are not limited to Sf9 cells (see, e.g., ATCC® CRL-1711TM).
- the helper cell may comprises rep and/or cap genes that encode the Rep protein and/or Cap proteins for use in a method described herein.
- the packaging is performed in vitro.
- the one or more helper plasmids includes a first helper plasmid comprising a rep gene and a cap gene and a second helper plasmid comprising other genes that assist in AAV production, such as a E1a gene, a E1b gene, a E4 gene, a E2a gene, and a VA gene.
- the rep gene is a rep gene derived from AAV2 and the cap gene is derived from AAV5.
- Helper plasmids, and methods of making such plasmids are known in the art and commercially available (see, e.g., pDF6, pRep, pDM, pDG, pDP1rs, pDP2rs, pDP3rs, pDP4rs, pDP5rs, pDP6rs, pDG(R484E/R585E), and pDP8.ape plasmids from PlasmidFactory, Bielefeld, Germany; other products and services available from Vector Biolabs, Philadelphia, Pa.; Cellbiolabs, San Diego, Calif.; Agilent Technologies, Santa Clara, Calif.; and Addgene, Cambridge, Mass.; pxx6; Grimm et al.
- helper plasmids are produced or obtained, which comprise rep and cap ORFs for the desired AAV serotype and the adenoviral VA, E2A (DBP), and E4 genes under the transcriptional control of their native promoters.
- HEK293 cells available from ATCC® are transfected via CaPO 4 -mediated transfection, lipids or polymeric molecules such as Polyethylenimine (PEI) with the helper plasmid(s) and a plasmid containing a nucleic acid vector described herein.
- PEI Polyethylenimine
- Sf9-based producer stable cell lines are infected with a single recombinant baculovirus containing the nucleic acid vector.
- HEK293 or BHK cell lines are infected with a HSV containing the nucleic acid vector and optionally one or more helper HSVs containing rep and cap ORFs as described herein and the adenoviral VA, E2A (DBP), and E4 genes under the transcriptional control of their native promoters.
- the HEK293, BHK, or Sf9 cells are then incubated for at least 60 hours to allow for rAAV particle production.
- the rAAV particles can then be purified using any method known the art or described herein, e.g., by iodixanol step gradient, CsCl gradient, chromatography, or polyethylene glycol (PEG) precipitation.
- the disclosure also contemplates host cells that comprise at least one of the disclosed rAAV particles, expression constructs, or nucleic acid vectors.
- host cells include mammalian host cells, with human host cells being preferred, and may be either isolated, in cell or tissue culture.
- the transformed host cells may be comprised within the body of a non-human animal itself.
- compositions comprising rAAV particles or nucleic acids described herein.
- rAAV particles described herein are added to a composition, e.g., a pharmaceutical composition.
- the composition comprises a pharmaceutically acceptable carrier.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the rAAV particle is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum oil such as mineral oil, vegetable oil such as peanut oil, soybean oil, and sesame oil, animal oil, or oil of synthetic origin. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers.
- Non-limiting examples of pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline, syrup, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, polyacrylic acids, lubricating agents (such as talc, magnesium stearate, and mineral oil), wetting agents, emulsifying agents, suspending agents, preserving agents (such as methyl-, ethyl-, and propyl-hydroxy-benzoates), and pH adjusting agents (such as inorganic and organic acids and bases).
- lactose dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium si
- carriers include phosphate buffered saline, HEPES-buffered saline, and water for injection, any of which may be optionally combined with one or more of calcium chloride dihydrate, disodium phosphate anhydrous, magnesium chloride hexahydrate, potassium chloride, potassium dihydrogen phosphate, sodium chloride, or sucrose.
- carriers that might be used include saline (e.g., sterilized, pyrogen-free saline), saline buffers (e.g., citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (for example, serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. USP grade carriers and excipients are particularly useful for delivery of rAAV particles to human subjects.
- saline e.g., sterilized, pyrogen-free saline
- saline buffers e.g., citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer
- amino acids e.g., citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer
- amino acids e.g., citrate buffer, phosphate buffer,
- compositions may further optionally comprise a liposome, a lipid, a lipid complex, a microsphere, a microparticle, a nanosphere, or a nanoparticle, or may be otherwise formulated for administration to the cells, tissues, organs, or body of a subject in need thereof.
- Methods for making such compositions are well known and can be found in, for example, Remington: The Science and Practice of Pharmacy, 22 nd edition, Pharmaceutical Press, 2012.
- compositions may contain at least about 0.1% of the therapeutic agent (e.g., rAAV particle) or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 70% or 80% or more of the weight or volume of the total formulation.
- the amount of therapeutic agent(s) (e.g., rAAV particle) in each therapeutically-useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound.
- a composition described herein may be administered to a subject in need thereof, such as a subject having Friedreich's ataxia.
- a method described herein may comprise administering a composition comprising rAAV particles as described herein to a subject in need thereof.
- the subject is a human subject.
- the subject has or is suspected of having a disease that may be treated with gene therapy, such as Friedreich's ataxia.
- the method comprises administering a therapeutically effective amount of an rAAV particle or a composition as described herein to a subject having Friedreich's ataxia.
- compositions described above or elsewhere herein are typically administered to a subject in an effective amount, that is, an amount capable of producing a desirable result.
- the desirable result will depend upon the active agent being administered.
- an effective amount of rAAV particles may be an amount of the particles that are capable of transferring an expression construct to a host organ, tissue, or cell.
- a therapeutically acceptable amount may be an amount that is capable of treating a disease, e.g., Friedreich's ataxia.
- dosage for any one subject depends on many factors, including the subject's size, body surface area, age, the particular composition to be administered, the active ingredient(s) in the composition, time and route of administration, general health, and other drugs being administered concurrently.
- the rAAV particle or nucleic acid vector may be delivered in the form of a composition, such as a composition comprising the active ingredient, such as a rAAV particle described herein, and a pharmaceutically acceptable carrier as described herein.
- a composition such as a composition comprising the active ingredient, such as a rAAV particle described herein, and a pharmaceutically acceptable carrier as described herein.
- the rAAV particles or nucleic acid vectors may be prepared in a variety of compositions, and may also be formulated in appropriate pharmaceutical vehicles for administration to human or animal subjects.
- the number of rAAV particles administered to a subject may be on the order ranging from 10 6 to 10 14 particles/ml or 10 3 to 10 15 particles/ml, or any values therebetween for either range, such as for example, about 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 particles/ml. In one embodiment, rAAV particles of higher than 10 13 particles/ml are be administered.
- the number of rAAV particles administered to a subject may be on the order ranging from 10 6 to 10 14 vector genomes(vgs)/ml or 10 3 to 10 15 vgs/ml, or any values therebetween for either range, such as for example, about 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 vgs/ml.
- rAAV particles of higher than 10 13 vgs/ml are be administered.
- the rAAV particles can be administered as a single dose, or divided into two or more administrations as may be required to achieve therapy of the particular disease or disorder being treated.
- the number of rAAV particles administered to a subject may be on the order ranging from 10 6 -10 14 vg/kg, or any values therebetween, such as for example, about 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 vgs/mg. In some embodiments, the number of rAAV particles administered to a subject may be on the order ranging from 10 12 -10 14 vgs/kg.
- rAAV particles may be administered in combination with other agents as well, such as, e.g., proteins or polypeptides or various pharmaceutically-active agents, including one or more systemic or topical administrations of therapeutic polypeptides, biologically active fragments, or variants thereof.
- agents such as, e.g., proteins or polypeptides or various pharmaceutically-active agents, including one or more systemic or topical administrations of therapeutic polypeptides, biologically active fragments, or variants thereof.
- agents e.g., proteins or polypeptides or various pharmaceutically-active agents, including one or more systemic or topical administrations of therapeutic polypeptides, biologically active fragments, or variants thereof.
- agents may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues.
- the rAAV particles may thus be delivered along with various other agents as required in the particular instance.
- Such compositions may be purified from host cells or other biological sources, or alternatively may be chemically
- rAAV particles in suitably formulated pharmaceutical compositions disclosed herein either subcutaneously, intraocularly, intravitreally, subretinally, parenterally, intravenously (IV), intracerebro-ventricularly, intramuscularly, intrathecally (IT), intracisternally, orally, intraperitoneally, by oral or nasal inhalation, or by direct injection to one or more cells, tissues, or organs by direct injection.
- the administration is a route suitable for systemic delivery, such as by intravenous injection.
- administering” or “administration” means providing a material to a subject in a manner that is pharmacologically useful.
- IV dosing is an advantageous route to transduce the heart, it does not have high translational feasibility for CNS disorders because of the high dose requirement, high distribution to peripheral tissues and reduced efficiency for CNS transduction (Schuster, D. et al., Front Neuronat., 8:42, 2014).
- intrathecal (IT) dosing of AAV9 e.g., via lumbar cistern or cisterna magna
- I intrathecal
- rAAV particles or compositions comprising rAAV particles that comprise (or package) FXN transgene are administered via intravenous (IV) injection.
- rAAV particles or compositions comprising rAAV particles that comprise (or package) FXN transgene are administered via intrathecal (IT) injection. In some embodiments, rAAV particles or compositions comprising rAAV particles that comprise (or package) FXN transgene are administered via intracisternal injection, so as to deliver the rAAV particles within a cistern of the brain. In some embodiments, rAAV particles or compositions comprising rAAV particles that package FXN transgene are administered via both an intravenous injection and an intrathecal injection, or via an intravenous injection and an intracisternal injection.
- more than two (e.g., three, or four) of the above described routes of administration are utilized.
- the ratio of rAAV particles administered to the subject via intravenous injection to rAAV particles administered to the subject via intrathecal injection is in the range of 10:1 to 1:10 (e.g., 10:1, 8:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:5, 1:8, 1:10), or 50:1 to 1:50 (e.g., 50:1, 40:1, 25:1, 30:1, 10:1, 1:1, 1:10, 1:30, 1:25, 1:40, 1:50), or 100:1 to 1:100 (e.g., 100:1, 80:1, 50:1, 10:1, 1:1, 1:10, 1:50, 1:80, 1:100), or 1000:1 to 1:1000 (e.g., 1000:1, 800:1, 500:1, 100:1, 1:1, 1:100, 1:500, 1:800, 1:1000).
- 10:1 to 1:10 e.g., 10:1, 8:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:5, 1:8, 1:10
- 50:1 to 1:50
- the ratio of rAAV particles administered to the subject via intravenous injection to rAAV particles administered to the subject via intracisternal injection is in the range of 10:1 to 1:10 (e.g., 10:1, 8:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:5, 1:8, 1:10), or 50:1 to 1:50 (e.g., 50:1, 40:1, 25:1, 30:1, 10:1, 1:1, 1:10, 1:30, 1:25, 1:40, 1:50), or 100:1 to 1:100 (e.g., 100:1, 80:1, 50:1, 10:1, 1:1, 1:10, 1:50, 1:80, 1:100), or 1000:1 to 1:1000 (e.g., 1000:1, 800:1, 500:1, 100:1, 1:1, 1:100, 1:500, 1:800, 1:1000).
- 10:1 to 1:10 e.g., 10:1, 8:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:5, 1:8, 1:10
- the ratio of rAAV particles administered to the subject via intravenous injection to rAAV particles administered to the subject via intrathecal injection is 1:10. In some embodiments, the ratio of rAAV particles administered to the subject via intravenous injection to rAAV particles administered to the subject via intracisternal injection is 1:10. In some embodiments, compositions administered via intravenous, intrathecal, and/or intracisternal injection may have the same number of particles or viral genomes per unit volume. However, in some embodiments compositions having different titers may be used for different routes of administration. Also, different compositions having different components in addition to the viral particles may be used for different routes of administration.
- rAAV particle or nucleic acid vector compositions The amount of rAAV particle or nucleic acid vector compositions and time of administration of such compositions will be within the purview of the skilled artisan having benefit of the present teachings. It is likely, however, that the administration of therapeutically-effective amounts of the disclosed compositions may be achieved by a single administration, such as for example, a single injection of sufficient numbers of infectious particles to provide therapeutic benefit to the patient undergoing such treatment. Alternatively, in some circumstances, it may be desirable to provide multiple, or successive administrations of the rAAV particle compositions, either over a relatively short, or a relatively prolonged period of time, as may be determined by the medical practitioner overseeing the administration of such compositions.
- the administration of rAAV comprising FXN transgene via the two or more routes is performed simultaneously, or within 10 min of each other. In some embodiments, when more than one route of administration is utilized, the administration of rAAV comprising FXN transgene via the two or more routes is staggered, so that administration via the second route is performed 10 min, 20 min, 30 min 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, or 24 h after the administration via the first route.
- the administration of rAAV comprising FXN transgene via the two or more routes is altered, so that administration via the second route replaces administration via the first route on a routine basis (e.g., for once a day schedule, administration via first route on day 1, administration via second route on day 2, administration via first route on day 3, administration via second route on day 4, and so on).
- the number of rAAV particles administered to a subject may be on the order ranging from 10 6 to 10 14 particles/mL or 10 3 to 10 13 particles/mL, or any values therebetween for either range, such as for example, about 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 particles/mL.
- rAAV particle compositions of lower than 10 7 particles/mL, for example lower than 10 3 particles/mL are administered.
- rAAV particle compositions of higher than 10 13 particles/mL, for example higher than 10 15 particles/mL are administered.
- the number of rAAV particles administered to a subject may be on the order ranging from 10 6 to 10 14 vector genomes(vgs)/mL or 10 3 to 10 15 vgs/mL, or any values there between for either range, such as for example, about 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 vgs/mL.
- rAAV particle compositions of higher than 10 13 vgs/mL, for example higher than 10 15 vgs/mL are administered.
- 0.0001 mL to 10 mLs are delivered to a subject (e.g., via one or more routes of administration as described in this application).
- IV and IT injections are routine non-surgical procedures that are often done in an outpatient setting with minimal risk (Mattar, C. et al., FASEB J, 29(9):3876, 2015; Gray, S. et al., Gene Ther, 20(4):450-9, 2013; Federici, T. et al., Gene Ther, 19(8):852, 2012; Snyder, B. et al., Hum Gene Ther, 22(9):1129, 2011).
- the pharmaceutical forms of the rAAV particle compositions suitable for injectable use include sterile aqueous solutions or dispersions.
- the form is sterile and fluid to the extent that easy syringability exists.
- the form is stable under the conditions of manufacture and storage and is preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the form is sterile.
- the carrier can be a solvent or dispersion medium containing, for example, water, saline, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
- Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, intravitreal, subretinal, subcutaneous and intraperitoneal administration.
- a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure.
- one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and the general safety and purity standards as required by, e.g., FDA Office of Biologics standards.
- Sterile injectable solutions are prepared by incorporating the rAAV particles in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization or another sterilization technique.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- composition may include rAAV particles, either alone, or in combination with one or more additional active ingredients, which may be obtained from natural or recombinant sources or chemically synthesized.
- Toxicity and efficacy of the compositions utilized in methods of the disclosure can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD50 (the dose lethal to 50% of the population).
- the dose ratio between toxicity and efficacy the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Those compositions that exhibit large therapeutic indices are preferred. While those that exhibit toxic side effects may be used, care should be taken to design a delivery system that minimizes the potential damage of such side effects.
- the dosage of compositions as described herein lies generally within a range that includes an ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- Non-limiting examples of non-human primate subjects include macaques (e.g., cynomolgus or rhesus macaques), marmosets, tamarins, spider monkeys, owl monkeys, vervet monkeys, squirrel monkeys, baboons, gorillas, chimpanzees, and orangutans.
- the subject is a human subject.
- Other exemplary subjects include domesticated animals such as dogs and cats; livestock such as horses, cattle, pigs, sheep, goats, and chickens; and other animals such as mice, rats, guinea pigs, and hamsters.
- the subject has or is suspected of having a disease that may be treated with gene therapy.
- the subject has or is suspected of having Friedreich's ataxia.
- Friedreich's ataxia is a rare inherited disease that causes degeneration of the spinal cord and peripheral nervous system.
- Subjects with FRDA generally have an expanded number of GAA repeats in the FXN gene.
- a subject generally must have both copies of the FXN with expanded repeats to develop FRDA, although about 2 percent of subjects have one copy of the FXN gene with expanded repeats and another different type of mutation in the other copy of the FXN gene.
- FRDA FRDA Symptoms of FRDA include gait ataxia, loss of sensation in the extremities, loss of tendon reflexes, scoliosis, dysarthria, hearing loss, vision loss, chest pain, shortness of breath, and heart palpitations. Subjects with FRDA may also develop carbohydrate intolerance or diabetes. Subjects with fewer than 300 repeats may develop symptoms later in life than those with additional repeats.
- Subject having FRDA can be identified by the skilled practitioner using methods known in the art or described herein, e.g., using genetic testing, electromyogram (EMG), nerve conduction studies, electrocardiogram (ECG), echocardiogram, blood tests for elevated glucose and vitamin E, magnetic resonance imaging (MRI) or computed tomography (CT) scans, and combinations thereof.
- EMG electromyogram
- ECG electrocardiogram
- MRI magnetic resonance imaging
- CT computed tomography
- FRDA Friedrich ataxia
- FXN frataxin gene
- Deficiency in frataxin expression results in severe mitochondrial dysfunction leading to progressive gait abnormality, impaired muscle coordination, muscle weakness, hyporeflexia, dysmetria, dysarthria, and hypertrophic cardiomyopathy.
- FRDA which is the most common occurring autosomal recessive ataxia, affecting 1 in 50,000 people worldwide.
- Precise quantification of frataxin levels is critical for establishing the effectiveness of potential therapies. Therefore, methods that improve detection of FXN expression will facilitate the implementation of novel therapies into a clinical setting.
- the overall objective was to establish an approach for effective gene transfer and quantification of frataxin levels sufficient to restore mitochondrial function.
- Stable isotope labeling of amino acids in cell culture or in mammals is a novel and sensitive mass spectrometry based approach used herein for the quantification of frataxin levels; therefore enabling determination of required levels for correction of FXN deficiency.
- a rAAV2/9-FXN vector expressing codon optimized human FXN was generated for use in models of FRDA.
- rAAV2/9 means that the nucleic acid vector contained AAV2 ITRs and the capsid encapsidating the nucleic acid vector was an AAV9 capsid.
- a map of a non-limiting plasmid containing the FXN expression construct is shown in FIG. 1 .
- the sequence of the plasmid is below.
- the sequence of the Desmin promoter in the plasmid is also shown (SEQ ID NO: 2, and see also FIG. 6 ).
- the frataxin gene sequence was codon-optimized using LifeTechnologies strategy using GeneOptimizer® software which calculates the optimal DNA sequence needed to encode the protein of interest (gene optimization).
- a polypeptide translation is as follows:
- Renal epithelial cells were isolated from control and FRDA patients, and SILAC was used to quantify AAV-mediated FXN expression in-vitro.
- Induced pluripotent stem cells IPC
- AAV-mediated correction of FXN was verified by increased mitochondrial activity including reduced iron deposition and increased aconitase function in FRDA cells.
- Preliminary results showed that SILAC/M was able to accurately measure endogenous and vector derived FXN expression in-vitro and in-vivo.
- improvement in mitochondrial function was correlated with levels of FXN expression in vitro.
- a clinical candidate vector was designed to express frataxin.
- the vector contained an expression cassette with human Desmin (DES) promoter driving codon-optimized human FXN with a truncated human FXN 3′ UTR.
- the expression cassette was flanked by AAV2 ITRs.
- the plasmid containing the expression cassette is shown in FIG. 1 and is further described in Example 1.
- the plasmid was used with AAV2 rep and AAV9 capsid helper plasmids to package the vector in an AAV9 capsid, resulting in rAAV2/9-FXN, which was used in all of the studies described below.
- FA2 cells are renal epithelial cells that were derived from FRDA patients ( FIG. 2A ).
- Induced pluripotent stem cells (IPSCs) were generated from the FA2 cells ( FIG. 2B ) and were differentiated into cardiomyocytes ( FIG. 2C ) and neural progenitor cells. Cardiomyocyte differentiation took about two weeks, whereas neural progenitor cell differentiation took about three weeks.
- the IPSC differentiation to cardiomyocytes and progenitor cells was validated by assessing cardiac and neuronal markers. NKX2.5 and TroponinT were used as markers of cardiomyocytes. The IPSCs differentiated into cardiomyocytes expressed both markers ( FIG. 3A ). Neurofluor CDr3 was used to confirm neural progenitor cell differentiation. The IPSCs differentiated into neural progenitors stained positive with Neurofluor CDr3 ( FIG. 3B ).
- FA2 cells were transiently transfected with the plasmid containing the FXN expression construct and FXN protein levels were analyzed by Western Blot and the Li-COR Odyssey Imaging system. FA2 transiently transfected cells showing dose dependent increases of FXN ( FIG. 4 ).
- aconitase activity assay was used to assess mitochondrial health in FA2 cells.
- Aconitase is a robust indicator of mitochondrial health.
- FA2 cells were transiently transfected with the plasmid containing the FXN expression construct.
- Aconitase activity was higher in FA2 cells transfected with the plasmid than in FA2 cells not transfected with the plasmid ( FIGS. 5A and 5B ).
- inventive embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed.
- inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein.
- a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
- “at least one of A and B” can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Provided herein are nucleic acids, recombinant adeno-associated viral particles, compositions and methods related to treating Friedreich's ataxia. In some examples, the nucleic acids, recombinant adeno-associated viral particles, compositions and methods involve use of a FXN coding sequence, a truncated FXN 3′ UTR, and a promoter.
Description
- This Application is a Continuation of U.S. application Ser. No. 16/745,962, filed Jan. 17, 2020, entitled “AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA”, which is a Continuation of U.S. application Ser. No. 15/568,961, filed Oct. 24, 2017, entitled “AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA”, which is a national stage filing under 35 U.S.C. 371 of International Patent Application Serial No. PCT/US2016/029084, filed Apr. 23, 2016, entitled “AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA”, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 62/152,780, entitled “AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA” filed Apr. 24, 2015, each of which is herein incorporated by reference in its entirety.
- Friedreich's ataxia is a genetic disease that causes damage to the nervous system, resulting in degeneration of the spinal cord and peripheral nerves. Friedreich's ataxia is caused by a mutation in the FXN gene that results in an expansion of an intronic GAA repeat, which leads to reduced expression of the mitochondrial protein frataxin. There is currently no approved cure for Friedreich's ataxia.
- Aspects of the disclosure relate to nucleic acids, recombinant adeno-associated virus (rAAV) particles, compositions, and methods related to gene therapy for Friedreich's ataxia (FRDA).
- As described herein, a rAAV nucleic acid vector was designed containing a codon-optimized human FXN gene with a truncated
human FXN 3′ UTR, operably linked to a promoter. When this vector was delivered in a rAAV particle to cardiomyocytes differentiated from induced pluripotent stem cells (IPSC) derived from FRDA, the cells had increased mitochondrial activity. This improvement in mitochondrial activity was correlated with increased levels of FXN expression in vitro. It is believed that this vector may be useful for treatment of FRDA. - In some aspects, the disclosure provides a nucleic acid comprising an expression construct comprising a human frataxin (FXN) coding sequence and a truncated
human FXN 3′ untranslated region (UTR) operably linked to a promoter (e.g., a Desmin promoter, a CBA promoter, a hFXNPro, or other suitable promoter), wherein the expression construct is flanked on each side by an inverted terminal repeat sequence (e.g., an AAV ITR). - In some embodiments, the human FXN coding sequence is codon-optimized for expression in human cells. In some embodiments, the FXN coding sequence comprises the sequence of SEQ ID NO: 1. In some embodiments, the promoter comprises one or more of the following: a Desmin promoter, a chicken β-actin (CBA) promoter, or an endogenous human FXN promoter (hFXNPro), or a fragment or derivative of one or more thereof sufficient to drive expression of the FXN coding sequence (e.g., in human cells). In some embodiments, the Desmin promoter comprises the sequence of SEQ ID NO: 2. In some embodiments, the CBA promoter comprises the sequence of SEQ ID NO: 7. In some embodiments, the hFXNPro comprises the sequence of SEQ ID NO: 8. In some embodiments, the truncated
human FXN 3′ UTR has the sequence of SEQ ID NO: 3. In some embodiments, the expression construct comprises the sequence of SEQ ID NO: 4 (or a portion thereof comprising a gene of interest under the control of a promoter of interest, optionally flanked by ITR sequences). In some embodiments, the nucleic acid is a recombinant adeno-associated virus (rAAV) vector. In some embodiments, the nucleic acid is a single-stranded or self-complementary rAAV nucleic acid vector. - Other aspects of the disclosure relate to a recombinant adeno-associated virus (rAAV) particle comprising a nucleic acid as described herein. In some embodiments, the nucleic acid comprises an expression construct comprising a human frataxin (FXN) coding sequence and a truncated
human FXN 3′ untranslated region (UTR) operably linked to a promoter (e.g., a Desmin promoter, a CBA promoter, a hFXNPro, or other suitable promoter), wherein the expression construct is flanked on each side by an inverted terminal repeat sequence. - In some embodiments, the human FXN coding sequence is codon-optimized for expression in human cells. In some embodiments, the FXN coding sequence comprises the sequence of SEQ ID NO: 1. In some embodiments, the promoter comprises one or more of the following: a Desmin promoter, a chicken β-actin (CBA) promoter, or an endogenous human FXN promoter (hFXNPro), or a fragment or derivative of one or more thereof sufficient to drive expression of the FXN coding sequence (e.g., in human cells). In some embodiments, the Desmin promoter comprises the sequence of SEQ ID NO: 2. In some embodiments, the CBA promoter comprises the sequence of SEQ ID NO: 7. In some embodiments, the hFXNPro comprises the sequence of SEQ ID NO: 8. In some embodiments, the truncated
human FXN 3′ UTR has the sequence of SEQ ID NO: 3. In some embodiments, the expression construct comprises the sequence of SEQ ID NO: 4 (or a portion thereof comprising a gene of interest under the control of a promoter of interest, optionally flanked by ITR sequences). In some embodiments, the nucleic acid is a recombinant adeno-associated virus (rAAV) vector. In some embodiments, the nucleic acid is a single-stranded or self-complementary rAAV nucleic acid vector. - In some embodiments, the rAAV particle is an AAV9 particle.
- In yet other aspects, the disclosure relates to a composition comprising a plurality of an rAAV particle as described herein. In some embodiments, the rAAV particle comprises a nucleic acid as described herein.
- In some embodiments, the human FXN coding sequence is codon-optimized for expression in human cells. In some embodiments, the FXN coding sequence comprises the sequence of SEQ ID NO: 1. In some embodiments, the promoter comprises one or more of the following: a Desmin promoter, a chicken β-actin (CBA) promoter, or an endogenous human FXN promoter (hFXNPro), or a fragment or derivative of one or more thereof sufficient to drive expression of the FXN coding sequence (e.g., in human cells). In some embodiments, the Desmin promoter comprises the sequence of SEQ ID NO: 2. In some embodiments, the CBA promoter comprises the sequence of SEQ ID NO: 7. In some embodiments, the hFXNPro comprises the sequence of SEQ ID NO: 8. In some embodiments, the truncated
human FXN 3′ UTR has the sequence of SEQ ID NO: 3. In some embodiments, the expression construct comprises the sequence of SEQ ID NO: 4 (or a portion thereof comprising a gene of interest under the control of a promoter of interest, optionally flanked by ITR sequences). In some embodiments, the nucleic acid is a recombinant adeno-associated virus (rAAV) vector. In some embodiments, the nucleic acid is a single-stranded or self-complementary rAAV nucleic acid vector. - In some embodiments, the rAAV particle is an AAV9 particle (e.g., the rAAV particle comprises viral capsid proteins of serotype 9).
- In some embodiments, the composition further comprises a pharmaceutically acceptable carrier.
- In other aspects, the disclosure provides a method of treating Friedreich's ataxia, the method comprising administering a therapeutically effective amount of an rAAV particle as described above or as described elsewhere herein or a composition as described above or as described elsewhere herein to a subject having Friedreich's ataxia. In some embodiments, the rAAV particle or composition are administered via intravenous injection. In some embodiments, the rAAV particle or composition are administered via intrathecal injection. In some embodiments, the rAAV particle or composition are administered via intracisternal injection. In some embodiments, the rAAV particle or composition are administered via intravenous injection and intrathecal injection. In some embodiments, the rAAV particle or composition are administered via intravenous injection and intracisternal injection.
- In some embodiments, the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intrathecal injection is between 10:1 and 1:1 (e.g., around 5:1, or around 10:1). In some embodiments, the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intrathecal injection is between 1:1 and 1:10 (e.g., around 1:5, or around 1:10). In some embodiments, the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intracisternal injection is between 10:1 and 1:1 (e.g., around 5:1, or around 10:1). In some embodiments, the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intracisternal injection is between 1:1 and 1:10 (e.g., around 1:5, or around 1:10).
- The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
-
FIG. 1 is a non-limiting plasmid map showing an expression construct containing a Desmin (DES) promoter, a codon-optimized human FXN coding sequence, and a truncatedhuman FXN 3′ UTR, the expression construct flanked by inverted terminal repeat sequences (ITRs). -
FIG. 2A shows an exemplary photograph of renal epithelial cells (REC) isolated from FRDA patients. -
FIG. 2B shows an exemplary photograph of induced pluripotent stem cells (IPSCs) generated from the RECs. -
FIG. 2C shows a photograph of a contracting cardiomyocyte generated from the IPSCs. -
FIG. 3A shows a series of exemplary photographs of cardiomyocytes generated from the IPSCs stained with different markers. (i) shows DAPI staining, (ii) shows NKX2.5 staining, (iii) shows TroponinT staining, and (iv) shows an overlay of (i)-(iii). -
FIG. 3B shows a series of exemplary photographs of neural progenitor cells (NPCs) generated from the IPSCs stained with different markers. (v) and (vi) show staining with Neurofluor CDr3 and Hoechst dye 33258. (vii) and (viii) show phase images of NPC cell morphology. -
FIG. 4 shows an image of an exemplary Western blot stained with an anti-frataxin antibody. “+” is FA2 cells transiently transfected with the FXN expression plasmid. “−”is FA2 cells that are not transfected. 1 ug, 5 ug, and 10 ug are amounts of purified FXN. -
FIG. 5A shows exemplary aconitase activity in FRDA patient-derived cells. FA2=untreated FRDA cells, FA2+FXN=FRDA cells transiently transfected with the FXN expression plasmid, CTRL=Healthy control cells; CTRL+FXN=healthy control cells transiently transfected with the FXN expression plasmid. -
FIG. 5B shows exemplary aconitase activity in FRDA patient-derived cells. FA2 CTRL=FRDA cell without transfection, FA2 TX 1 μg=FRDA cells transfected with 1 μg of plasmid, FA2 TX 5 μg=FRDA cells transfected with 5 μg of plasmid, FA2 TX 10 μg=FRDA cells transfected with 10 μg of plasmid. -
FIG. 6 shows an exemplary map of a Desmin promoter. - Friedrich's ataxia (FRDA) is an autosomal recessive disorder caused by a trinucleotide repeat expansion (TNR) of the frataxin (FXN) gene, on chromosome 9q12-13, which leads to a deficiency in the mitochondrial protein frataxin (FXN). FRDA affects 1 in 50,000 people worldwide and is characterized by progressive neural degeneration, such as ataxia, sensory loss, muscle weakness, and hypertrophic cardiomyopathy. Symptoms generally present at puberty and patients have a shorter than normal life expectancy reaching 40-50 years of age.
- Frataxin is a highly conserved, 210 amino acid (˜17 kDa) protein encoded in the nucleus. While frataxin's specific function remains unclear, homozygous deletions are embryonically lethal. Evidence suggests frataxin is involved in iron metabolism, iron storage, iron-sulfur cluster (ISC) formation, and protection against reactive oxygen species (ROS). Dysregulation of FXN leads to iron accumulation in the mitochondria and insufficient iron in the cytoplasm. Excess mitochondrial iron increases the incidence of iron-catalyzed reduction of hydrogen peroxide generating toxic ROS. The increase in ROS disrupts iron homeostasis in the mitochondria and affects the ISC aconitase, a major component of cellular respiration.
- Currently patients with FRDA receive palliative care as there is no FDA approved treatment.
- The major neurological symptoms of FRDA include muscle weakness and ataxia, a loss of balance and coordination. FRDA mostly affects the spinal cord and the peripheral nerves that connect the spinal cord to the body's muscles and sensory organs. FRDA affects the function of the cerebellum and also the musculature of the heart. There is a high prevalence of diabetes in FRDA patients as well. FXN deficiency in pancreatic islet cells causes diabetes (Ristow, M, et al., J Clin Invest. 112(4): 527-534, 2003).
- In some embodiments, the neurological degeneration in FRDA patients needs to be addressed. In some embodiments, the cardiac disease in FRDA patients needs to be addressed. In some embodiments, there is a need for strategies to treat the systemic manifestations of the disease, which may include disease in the heart, CNS and/or pancreatic islet cells.
- Over the past decade the field of gene therapy for the treatment of genetic diseases has made a resurgence including marketing authorization for an AAV product in the EU. In some embodiments, the fundamental principle is based on the ability to restore proper gene function in target tissues.
- Herein are disclosed nucleic acids, compositions and methods that can be used to achieve global gene transfer using AAV vectors, and that can target both the neurological and cardiac impairment in FRDA. Herein, “global” refers to an entire organ, system of the body (e.g., CNS) or body. The disclosed nucleic acids encoding FXN, compositions and methods, which relate to both choice of promoter and routes of rAAV particle delivery to a subject, enable targeting multiple affected organs in a subject with FRDA, including cardiac muscle, pancreas (e.g., pancreatic islet cells), and/or CNS (e.g., dorsal root ganglia, and the cerebellum).
- According to the disclosure, a gene therapy strategy that increases frataxin levels may be useful to treat FRDA or one or more symptoms thereof.
- Adeno-associated viruses (AAVs) are among the most common vectors used in gene therapy due to persistent, robust gene expression, a lack of toxicity, and limited immune response. However, challenges in AAV-mediated neural delivery and targeting have yet to be fully characterized.
- As described herein, a rAAV-FXN vector driven by a promoter sequence (e.g., a Desmin promoter) was developed and shown to be capable of increasing expression of frataxin and restoring mitochondrial function in cells from FRDA patients.
- Recombinant Adeno-Associated Virus (rAAV) Particles and Nucleic Acids
- Aspects of the disclosure relate to recombinant AAV (rAAV) particles and nucleic acids. In some embodiments, a nucleic acid is provided, the nucleic acid comprising an expression construct containing a FXN coding sequence (e.g., a human FXN coding sequence) linked to a promoter (e.g., a Desmin promoter, for example a human Desmin promoter, a CBA promoter, a hFXNPro, or other suitable promoter). In some embodiments, the expression construct further contains a
FXN 3′ untranslated region (UTR) that is 3′ to the FXN coding sequence. In some embodiments, the expression construct is flanked on each side by an inverted terminal repeat sequence (e.g., an AAV ITR). - Recombinant AAV (rAAV) nucleic acids are, herein, equivalent to rAAV nucleic acid vectors (e.g., a plasmid that is used to prepare a rAAV, a nucleic acid comprising a gene of interest and a promoter flanked by ITRs that are packaged in an rAAV particle, or other nucleic acid described herein that comprises or encodes a nucleic acid that is packaged in a rAAV, or that encodes one or more viral proteins). Accordingly, rAAV nucleic acids can be circular, linear, single-stranded, or double-stranded, depending on the context. In some embodiments, a nucleic acid is an RNA molecule. In some embodiments, a nucleic acid is a DNA molecule. In some embodiments, recombinant AAV (rAAV) vectors can be nucleic acid vectors that are used to transfect cells in which the expression construct that is comprised by the vector is packaged (or encapsidated) into rAAV particles. In some embodiments, rAAV vectors can be the nucleic acid flanked by ITRs (and including the ITRs) that is packaged in a rAAV.
- It should be appreciated that a composition or nucleic acid described herein with reference to a particular sequence (e.g., with reference to a particular SEQ ID NO:) can be provided as a composition or nucleic acid (e.g., RNA or DNA) comprising a single-stranded nucleic acid having that sequence, or a composition or nucleic acid (e.g., RNA or DNA) comprising a single-stranded nucleic acid having the complement of that sequence, or a composition or nucleic acid (e.g., RNA or DNA) comprising a double-stranded nucleic acid one strand of which has that sequence, or a composition or nucleic acid (e.g., RNA or DNA) comprising a portion of one or more of such nucleic acids, or a combination thereof.
- In some embodiments, the FXN coding sequence encodes a human frataxin protein. An exemplary human frataxin protein is shown below:
-
Exemplary human FXN protein (SEQ ID NO: 6) MWTLGRRAVAGLLASPSPAQAQTLTRVPRPAELAPLCGRRGLRTDIDATC TPRRASSNQRGLNQIWNVKKQSVYLMNLRKSGTLGHPGSLDETTYERLAE ETLDSLAEFFEDLADKPYTFEDYDVSFGSGVLTVKLGGDLGTYVINKQTP NKQIWLSSPSSGPKRYDWTGKNWVFSHDGVSLHELLAAELTKALKTKLDL SWLAYSGKDAIDIPSPVLRTLKAIRPRPQLHYAAEVCFLLLLLFIFFIPA FEDSWAMCHSSVERMCCLLPCPQVLIFNFYGRFFGLSDFLPHMIPLIFYN VLCLYLNITTFKKAK - In some embodiments, the FXN coding sequence is codon-optimized for expression in human cells, e.g., by adjusting codon usage within the coding sequence to codons commonly used by human cells. In some embodiments, the FXN coding sequence is further optimized to remove extra GC content, ribosomal binding sites, consensus and cryptic splice sites, repeats, and/or secondary structures. Optimization of coding sequences (e.g., codon-optimization) can be accomplished using any method known in the art, e.g., using GeneOptimizer® software from LifeTechnologies. In some embodiments, the codon-optimized human FXN coding sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence of SEQ ID NO: 1. In some embodiments, the codon-optimized human FXN coding sequence comprises the sequence of SEQ ID NO: 1.
-
-
(SEQ ID NO: 1) ATGTGGACACTGGGGAGAAGGGCCGTGGCTGGACTGCTGGCTTCTCCATC TCCAGCCCAGGCCCAGACCCTGACCAGAGTGCCTAGACCTGCCGAACTGG CCCCTCTGTGTGGCAGAAGAGGCCTGAGAACCGACATCGACGCCACCTGT ACCCCCAGAAGGGCCAGCAGCAATCAGCGGGGCCTGAATCAGATCTGGAA CGTGAAGAAACAGAGCGTGTACCTGATGAACCTGAGAAAGAGCGGCACCC TOGGCCACCCTGGAAGCCTGGATGAGACAACCTACGAGCGGCTGGCCGAG GAAACCCTGGATTCCCTGGCCGAGTTCTTCGAGGACCTGGCCGACAAGCC CTACACCTTCGAGGATTACGACGTGTCCTTCGGCAGCGGCGTGCTGACAG TGAAGCTGGGCGGAGATCTGGGCACCTACGTGATCAACAAGCAGACCCCC AACAAACAGATCTGGCTGAGCAGCCCCAGCAGCGGCCCCAAGAGATACGA TTGGACCGGCAAGAACTOGGTOTTCAGCCACGACGGCGTOTCCCTGCATG AGCTGCTGGCTGCCGAGCTGACCAAGGCCCTGAAAACAAAGCTGGACCTG AGCTGGCTGGCCTACAGCGGCAAAGATGCCATCGATATCCCCAGCCCCGT TTTAAGGACATTAAAAGCTATCAGGCCAAGACCCCAGCTTCATTATGCAG CTGAGGTCTGTTTTTTGTTGTTGTTGTTGTTTATTTTTTTTATTCCTGCT TTTGAGGACAGTTGGGCTATGTGTCACAGCTCTGTAGAAAGAATGTGTTG CCTCCTACCTTGCCCCCAAGTTCTGATTTTTAATTTCTATGGAAGATTTT TTGGATTGTCGGATTTCCTCCCTCACATGATACCCCTTATCTTTTATAAT GTCTTATGCCTATACCTGAATATAACAACCTTTAAAAAAGCAAAATAA - In some embodiments, the promoter is a Desmin promoter, or a fragment or variant thereof that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or more of the activity (e.g., promotion of transcription of a gene, such as in a neuronal or muscle cell) of a wild-type human Desmin promoter. In some embodiments, the promoter comprises two or more fragments of a Desmin promoter (e.g., an enhancer fragment and a basal promoter fragment, which may be fused together optionally with a spacer sequence). The fragment(s) may be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 200, 250, 500, 1000 or more nucleotides shorter than a wild-type human Desmin promoter. In some embodiments, the Desmin promoter comprises one or more of (e.g., one, two, three, or four of) a MEF2 responsive element, a MyoD E-box, a CACC box and a TATA box. In some embodiments, the promoter has a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence of SEQ ID NO: 2. In some embodiments, the promoter is a Desmin promoter having the sequence of SEQ ID NO: 2.
- Exemplary Desmin promoter sequence (potential MEF2 responsive element (with 9 bp AT-rick core) at position 65-73, MyoD E-box at position 97-102, CACC box at position 160-163 (binds nuclear factors present in cardiac and skeletal muscle myocytes), CACC box at position 176-179, CACC box at position 179-182, CACC box at position 253-256, MyoD E-box at position 270-275, CACC box at position 338-341, MyoD E-box at position 542-547, TATA box at position 585-590, and CACC box at position 696-699).
-
(SEQ ID NO: 2) GATCTTACCCCCTGCCCCCCACAGCTCCTCTCCTGTGCCTTGTTTCCCAG CCATGCGTTCTCCTCTATAAATACCCGCTCTGGTATTTGGGGTTGGCAGC TGTTGCTGCCAGGGAGATGGTTGGGTTGACATGCGGCTCCTGACAAAACA CAAACCCCTGGTGTGTGTGGGCGTGGGTGGTGTGAGTAGGGGGATGAATC AGGGAGGGGGCGGGGGACCCAGGGGGCAGGAGCCACACAAAGTCTGTGCG GGGGTGGGAGCGCACATAGCAATTGGAAACTGAAAGCTTATCAGACCCTT TCTGGAAATCAGCCCACTGTTTATAAACTTGAGGCCCCACCCTCGAGATA ACCAGGGCTGAAAGAGGCCCGCCTGGGGGCTGGAGACATGCTTGCTGCCT GCCCTGGCGAAGGATTGGCAGGCTTGCCCGTCACAGGACCCCCGCTGGCT GACTCAGGGGCGCAGGCCTCTTGCGGGGGAGCTGGCCTCCCCGCCCCCAC GGCCACGGGCCGCCCTTTCCTGGCAGGACAGCGGGATCTTGCAGCTGTCA GGGGAGGGGAGGCGGGGGCTGATGTCAGGAGGGATACAAATAGTGCCGAC GGCTGGGGGCCCTGTCTCCCCTCGCCGCATCCACTCTCCGGCCGGCCGCC TGTCCGCCGCCTCCTCCGTGCGCCCGCCAGCCTCGCCCGCGCCGTCACCG TGAGGCACTGGG - In some embodiments, the promoter is a Chicken β-actin (CBA) promoter, or a fragment or variant thereof that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or more of the activity (e.g., promotion of transcription of a gene, such as in a neuronal or muscle cell) of a wild-type full-length promoter. In some embodiments, the promoter comprises two or more fragments of a CBA promoter (e.g., an enhancer fragment and a basal promoter fragment, which may be fused together optionally with a spacer sequence). The fragment(s) may be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 200, 250, 500, 1000 or more nucleotides shorter than the full-length CBA promoter. In some embodiments, the CBA promoter comprises one or more of (e.g., one, two, three, or four of) a MEF2 responsive element, a MyoD E-box, a CACC box and a TATA box. In some embodiments, the promoter has a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence of SEQ ID NO: 7. In some embodiments, the promoter is a CBA promoter having the sequence of SEQ ID NO: 7.
-
Exemplary CBA promoter sequence (SEQ ID NO: 7) ctagatctgaattcggtaccctagttattaatagtaatcaattacggggt cattagttcatagcccatatatggagttccgcgttacataacttacggta aatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaat aatgacgtatgttcccatagtaacgccaatagggactttccattgacgtc aatgggtggactatttacggtaaactgcccacttggcagtacatcaagtg tatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcc cgcctggcattatgcccagtacatgaccttatgggactttcctacttggc agtacatctacgtattagtcatcgctattaccatggtcgaggtgagcccc acgttctgcttcactctccccatctcccccccctccccacccccaatttt gtatttatttattttttaattattttgtgcagcgatgggggcgggggggg ggggggggcgcgcgccaggcggggcggggcggggcgaggggcggggcggg gcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaa gtttccttttatggcgaggcggcggcggcggcggccctataaaaagcgaa gcgcgcggcgggcgggagtcgctgcgacgctgccttcgccccgtgccccg ctccgccgccgcctcgcgccgcccgccccggctctgactgaccgcgttac tcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattag cgcttggtttaatgacggcttgtttcttttctgtggctgcgtgaaagcct tgaggggctccgggagggccctttgtgcgggggggagcggctcggggggt gcgtgcgtgtgtgtgtgcgtggggagcgccgcgtgcggcccgcgctgccc ggcggctgtgagcgctgcgggcgcggcgcggggctttgtgcgctccgcag tgtgcgcgaggggagcgcggccgggggcggtgccccgcggtgcggggggg gctgcgaggggaacaaaggctgcgtgcggggtgtgtgcgtgggggggtga gcagggggtgtgggcgcggcggtcgggctgtaacccccccctgcaccccc ctccccgagttgctgagcacggcccggcttcgggtgcggggctccgtacg gggcgtggcgcggggctcgccgtgccgggcggggggtggcggcaggtggg ggtgccgggcggggcggggccgcctcgggccggggagggctcgggggagg ggcgcggcggcccccggagcgccggcggctgtcgaggcgcggcgagccgc agccattgccttttatggtaatcgtgcgagagggcgcagggacttccttt gtcccaaatctgtgcggagccgaaatctgggaggcgccgccgcaccccct ctagcgggcgcggggcgaagcggtgcggcgccggcaggaaggaaatgggc ggggagggccttcgtgcgtcgccgcgccgccgtccccttctccctctcca gcctcggggctgtccgcggggggacggctgccttcgggggggacggggca gggcggggttcggcttctggcgtgtgaccggcggctctagagcctctgct aaccatgttcatgccttcttctttttcctacagctcctgggcaacgtgct ggttattgtgctgtctcatcattttggcaaagaattcctcgaagatccga aggggttcaagcttaaaaa - In some embodiments, the promoter is a human FXN promoter (hFXNPro promoter), or a fragment or variant thereof that has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%, or more of the activity (e.g., promotion of transcription of a gene, such as in a neuronal or muscle cell) of a wild-type hFXNPro. In some embodiments, the promoter comprises two or more fragments of a hFXNPro (e.g., an enhancer fragment and a basal promoter fragment, which may be fused together optionally with a spacer sequence). The fragment(s) may be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 200, 250, 500, 1000 or more nucleotides shorter than a wild-type hFXNPro. In some embodiments, the hFXNPro comprises one or more of (e.g., one, two, three, or four of) a MEF2 responsive element, a MyoD E-box, a CACC box and a TATA box. In some embodiments, the promoter has a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence of SEQ ID NO: 8. In some embodiments, the promoter is a hFXNPro having the sequence of SEQ ID NO: 8.
-
Exemplary hFXNPro sequence (SEQ ID NO: 8) AAGAAAACTTTCACAATTTGCATCCCTTTGTAATATGTAACAGAAATAAA ATTCTCTTTTAAAATCTATCAACAATAGGCAAGGCACGGTGGCTCACGCC TGTCGTCTCAGCACTTTGTGAGGCCCAGGCGGGCAGATCGTTTGAGCCTA GAAGTTCAAGACCACCCTGGGCAACATAGCGAAACCCCCTTTCTACAAAA AATACAAAAACTAGCTGGGTGTGGTGGTGCACACCTGTAGTCCCAGCTAC TTGGAAGGCTGAAATGGGAAGACTGCTTGAGCCCGGGAGGGAGAAGTTGC AGTAAGCCAGGACCACACCACTGCACTCCAGCCTGGGCAACAGAGTGAGA CTCTGTCTCAAACAAACAAATAAATGAGGCGGGTGGATCACGAGGTCAGT AGATCGAGACCATCCTGGCTAACACGGTGAAACCCGTCTCTACTAAAAAA AAAAAAAAATACAAAAAATTAGCCAGGCATGGTGGCGGGCGCCTGTAGTC CCAGTTACTCGGGAGGCTGAGGCAGGAGAATGGCGTGAAACCGGGAGGCA GAGCTTGCAGTGAGCCGAGATCGCACCACTGCCCTCCAGCCTGGGCGACA GAGCGAGACTCCGTCTCAATCAATCAATCAATCAATAAAATCTATTAACA ATATTTATTGTGCACTTAACAGGAACATGCCCTGTCCAAAAAAAACTTTA CAGGGCTTAACTCATTTTATCCTTACCACAATCCTATGAAGTAGGAACTT TTATAAAACGCATTTTATAAACAAGGCACAGAGAGGTTAATTAACTTGCC CTCTGGTCACACAGCTAGGAAGTGGGCAGAGTACAGATTTACACAAGGCA TCCGTCTCCTGGCCCCACATACCCAACTGCTGTAAACCCATACCGGCGGC CAAGCAGCCTCAATTTGTGCATGCACCCACTTCCCAGCAAGACAGCAGCT CCCAAGTTCCTCCTGTTTAGAATTTTAGAAGCGGCGGGCCACCAGGCTGC agtctcccttgggtcaggggtcctggttgcactccgtgctttgcacaaag caggctctccatttttgttaaatgcacgaatagtgctaagctgggaagtt cttcctgaggtctaacctctagctgctcccccacagaagagtgcctgcgg ccagtggccaccaggggtcgccgcagcacccagcgctggagggcggagcg ggcggcagacccggagcagc - In some embodiments, the promoter has a sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% identical to the sequence identified as nucleotides 2312-2404 of GenBank accession No. NC_001510.1.
- In some embodiments, the
FXN 3′ untranslated region (UTR) is atruncated FXN 3′ UTR. In some embodiments, thetruncated FXN 3′ UTR is a truncatedhuman FXN 3′ UTR. In some embodiments, thetruncated FXN 3′ UTR is at least 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000 or more nucleotides shorter than a wild-type FXN 3′ UTR. In some embodiments, the 3′ UTR is truncated (e.g., by at least 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000 or more nucleotides) and the truncated sequence has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the corresponding sequence in a wild-type FXN 3′ UTR. In some embodiments, the 3′ UTR is truncated relative to the below wild-type FXN 3′ UTR. In some embodiments, the truncated 3′ UTR is no more than 2000, 1900, 1800, 1700, 1600, 1500, 1400, 1300, 1200, 1100, or 1000 nucleotides in length. -
Exemplary human FXN 3′ UTR (SEQ ID NO: 9) 1 ACTAGTGCCA CCATGTGGAC ACTGGGGAGA AGGGCCGTGG CTGGACTGCT GGCTTCTCCA 61 TCTCCAGCCC AGGCCCAGAC CCTGACCAGA GTGCCTAGAC CTGCCGAACT GGCCCCTCTG 121 TGTGGCAGAA GAGGCCTGAG AACCGACATC GACGCCACCT GTACCCCCAG AAGGGCCAGC 181 AGCAATCAGC GGGGCCTGAA TCAGATCTGG AACGTGAAGA AACAGAGCGT GTACCTGATG 241 AACCTGAGAA AGAGCGGCAC CCTGGGCCAC CCTGGAAGCC TGGATGAGAC AACCTACGAG 301 CGGCTGGCCG AGGAAACCCT GGATTCCCTG GCCGAGTTCT TCGAGGACCT GGCCGACAAG 361 CCCTACACCT TCGAGGATTA CGACGTGTCC TTCGGCAGCG GCGTGCTGAC AGTGAAGCTG 421 GGCGGAGATC TGGGCACCTA CGTGATCAAC AAGCAGACCC CCAACAAACA GATCTGGCTG 481 AGCAGCCCCA GCAGCGGCCC CAAGAGATAC GATTGGACCG GCAAGAACTG GGTGTTCAGC 541 CACGACGGCG TGTCCCTGCA TGAGCTGCTG GCTGCCGAGC TGACCAAGGC CCTGAAAACA 601 AAGCTGGACC TGAGCTGGCT GGCCTACAGC GGCAAAGATG CCATCGATAT CCCCAGCCCC 661 GTTTTAAGGA CATTAAAAGC TATCAGGCCA AGACCCCAGC TTCATTATGC AGCTGAGGTC 721 TGTTTTTTGT TGTTGTTGTT GTTTATTTTT TTTATTCCTG CTTTTGAGGA CAGTTGGGCT 781 ATGTGTCACA GCTCTGTAGA AAGAATGTGT TGCCTCCTAC CTTGCCCCCA AGTTCTGATT 841 TTTAATTTCT ATGGAAGATT TTTTGGATTG TCGGATTTCC TCCCTCACAT GATACCCCTT 901 ATCTTTTATA ATGTCTTATG CCTATACCTG AATATAACAA CCTTTAAAAA AGCAAAATAA 961 TAAGAAGGAA AAATTCCAGG AGGGAAAATG AATTGTCTTC ACTCTTCATT CTTTGAAGGA 1021 TTTACTGCAA GAAGTACATG AAGAGCAGCT GGTCAACCTG CTCACTGTTC TATCTCCAAA 1081 TGAGACACAT TAAAGGGTAG CCTACAAATG TTTTCAGGCT TCTTTCAAAG TGTAAGCACT 1141 TCTGAGCTCT TTAGCATTGA AGTGTCGAAA GCAACTCACA CGGGAAGATC ATTTCTTATT 1201 TGTGCTCTGT GACTGCCAAG GTGTGGCCTG CACTGGGTTG TCCAGGGAGA CATGCATCTA 1261 GTGCTGTTTC TCCCACATAT TCACATACGT GTCTGTGTGT ATATATATTT TTTCAATTTA 1321 AAGGTTAGTA TGGAATCAGC TGCTACAAGA ATGCAAAAAA TCTTCCAAAG ACAAGAAAAG 1381 AGGAAAAAAA GCCGTTTTCA TGAGCTGAGT GATGTAGCGT AACAAACAAA ATCATGGAGC 1441 TGAGGAGGTG CCTTGTAAAC ATGAAGGGGC AGATAAAGGA AGGAGATACT CATGTTGATA 1501 AAGAGAGCCC TGGTCCTAGA CATAGTTCAG CCACAAAGTA GTTGTCCCTT TGTGGACAAG 1561 TTTCCCAAAT TCCCTGGACC TCTGCTTCCC CATCTGTTAA ATGAGAGAAT AGAGTATGGT 1621 TGATTCCCAG CATTCAGTGG TCCTGTCAAG CAACCTAACA GGCTAGTTCT AATTCCCTAT 1681 TGGGTAGATG AGGGGATGAC AAAGAACAGT TTTTAAGCTA TATAGGAAAC ATTGTTATTG 1741 GTGTTGCCCT ATCGTGATTT CAGTTGAATT CATGTGAAAA TAATAGCCAT CCTTGGCCTG 1801 GCGCGGTGGC TCACACCTGT AATCCCAGCA CTTTTGGAGG CCAAGGTGGG TGGATCACCT 1861 GAGGTCAGGA GTTCAAGACC AGCCTGGCCA ACATGATGAA ACCCCGTCTC TACTAAAAAT 1921 ACAAAAAATT AGCCGGGCAT GATGGCAGGT GCCTGTAATC CCAGCTACTT GGGAGGCTGA 1981 AGCGGAAGAA TCGCTTGAAC CCAGAGGTGG AGGTTGCAGT GAGCCGAGAT CGTGCCATTG 2041 CACTGTAACC TGGGTGACTG AGCAAAACTC TGTCTCAAAA TAATAATAAC AATATAATAA 2101 TAATAATAGC CATCCTTTAT TGTACCCTTA CTGGGTTAAT CGTATTATAC CACATTACCT 2161 CATTTTAATT TTTACTGACC TGCACTTTAT ACAAAGCAAC AAGCCTCCAG GACATTAAAA 2221 TTCATGCAAA GTTATGCTCA TGTTATATTA TTTTCTTACT TAAAGAAGGA TTTATTAGTG 2281 GCTGGGCATG GTGGCGTGCA CCTGTAATCC CAGGTACTCA GGAGGCTGAG ACGGGAGAAT 2341 TGCTTGACCC CAGGCGGAGG AGGTTACAGT GAGTCGAGAT CGTACCTGAG CGACAGAGCG 2401 AGACTCCGTC TCAAAAAAAA AAAAAAGGAG GGTTTATTAA TGAGAAGTTT GGTCGAC - In some embodiments, the
truncated FXN 3′ UTR has the sequence of SEQ ID NO: 3. -
Exemplary truncated FXN 3′ UTR(SEQ ID NO: 3) AAGAAGGAAAAATTCCAGGAGGGAAAATGAATTGTCTTCACTCTTCATTC TTTGAAGGATTTACTGCAAGAAGTACATGAAGAGCAGCTGGTCAACCTGC TCACTGTTCTATCTCCAAATGAGACACATTAAAGGGTAGCCTACAAATGT TTTCAGGCTTCTTTCAAAGTGTAAGCACTTCTGAGCTCTTTAGCATTGAA GTGTCGAAAGCAACTCACACGGGAAGATCATTTCTTATTTGTGCTCTGTG ACTGCCAAGGTGTGGCCTGCACTGGGTTGTCCAGGGAGACATGCATCTAG TGCTGTTTCTCCCACATATTCACATACGTGTCTGTGTGTATATATATTTT TTCAATTTAAAGGTTAGTATGGAATCAGCTGCTACAAGAATGCAAAAAAT CTTCCAAAGACAAGAAAAGAGGAAAAAAAGCCGTTTTCATGAGCTGAGTG ATGTAGCGTAACAAACAAAATCATGGAGCTGAGGAGGTGCCTTGTAAACA TGAAGGGGCAGATAAAGGAAGGAGATACTCATGTTGATAAAGAGAGCCCT GGTCCTAGACATAGTTCAGCCACAAAGTAGTTGTCCCTTTGTGGACAAGT TTCCCAAATTCCCTGGACCTCTGCTTCCCCATCTGTTAAATGAGAGAATA GAGTATGGTTGATTCCCAGCATTCAGTGGTCCTGTCAAGCAACCTAACAG GCTAGTTCTAATTCCCTATTGGGTAGATGAGGGGATGACAAAGAACAGTT TTTAAGCTATATAGGAAACATTGTTATTGGTGTTGCCCTATCGTGATTTC AGTTGAATTCATGTGAAAATAATAGCCATCCTTGGCCTGGCGCGGTGGCT CACACCTGTAATCCCAGCACTTTTGGAGGCCAAGGTGGGTGGATCACCTG AGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGATGAAACCCCGTCTCT ACTAAAAATACAAAAAATTAGCCGGGCATGATGGCAGGTGCCTGTAATCC CAGCTACTTGGGAGGCTGAAGCGGAAGAATCGCTTGAACCCAGAGGTGGA GGTTGCAGTGAGCCGAGATCGTGCCATTGCACTGTAACCTGGGTGACTGA GCAAAACTCTGTCTCAAAATAATAATAACAATATAATAATAATAATAGCC ATCCTTTATTGTACCCTTACTGGGTTAATCGTATTATACCACATTACCTC ATTTTAATTTTTACTGACCTGCACTTTATACAAAGCAACAAGCCTCCAGG ACATTAAAATTCATGCAAAGTTATGCTCATGTTATATTATTTTCTTACTT AAAGAAGGATTTATTAGTGGCTGGGCATGGTGGCGTGCACCTGTAATCCC AGGTACTCAGGAGGCTGAGACGGGAGAATTGCTTGACCCCAGGCGGAGGA GGTTACAGTGAGTCGAGATCGTACCTGAGCGACAGAGCGAGACTCCGTCT CAAAAAAAAAAAAAAGGAGGGTTTATTAATGAGAAGTTTG - In some embodiments, the expression construct further contains a nucleic acid segment that encode a polyadenylation signal. In some embodiments, the nucleic acid segment is positioned 3′ to the
FXN 3′ UTR in the expression construct. - In some embodiments, the expression construct comprises the sequence of SEQ ID NO: 4 (or a portion thereof comprising a gene of interest under the control of a promoter of interest, optionally flanked by ITR sequences).
-
Exemplary expression construct (SEQ ID NO: 4) GATCTTACCCCCTGCCCCCCACAGCTCCTCTCCTGTGCCTTGTTTCCCAG CCATGCGTTCTCCTCTATAAATACCCGCTCTGGTATTTGGGGTTGGCAGC TGTTGCTGCCAGGGAGATGGTTGGGTTGACATGCGGCTCCTGACAAAACA CAAACCCCTGGTGTGTGTGGGCGTGGGTGGTGTGAGTAGGGGGATGAATC AGGGAGGGGGCGGGGGACCCAGGGGGCAGGAGCCACACAAAGTCTGTGCG GGGGTGGGAGCGCACATAGCAATTGGAAACTGAAAGCTTATCAGACCCTT TCTGGAAATCAGCCCACTGTTTATAAACTTGAGGCCCCACCCTCGAGATA ACCAGGGCTGAAAGAGGCCCGCCTGGGGGCTGGAGACATGCTTGCTGCCT GCCCTGGCGAAGGATTGGCAGGCTTGCCCGTCACAGGACCCCCGCTGGCT GACTCAGGGGCGCAGGCCTCTTGCGGGGGAGCTGGCCTCCCCGCCCCCAC GGCCACGGGCCGCCCTTTCCTGGCAGGACAGCGGGATCTTGCAGCTGTCA GGGGAGGGGAGGCGGGGGCTGATGTCAGGAGGGATACAAATAGTGCCGAC GGCTGGGGGCCCTGTCTCCCCTCGCCGCATCCACTCTCCGGCCGGCCGCC TGTCCGCCGCCTCCTCCGTGCGCCCGCCAGCCTCGCCCGCGCCGTCACCG TGAGGCACTGGGCAGGTAAGTATCAAAGTATCAAGGTTACAAGACAGGTT TAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTGCG TTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCT CCACAGGCTAGCCTCGAGAATTCACGCGTGGTACCTCTAGAGTCGACCGA TATCACTAGTGCCACCATGTGGACACTGGGGAGAAGGGCCGTGGCTGGAC TGCTGGCTTCTCCATCTCCAGCCCAGGCCCAGACCCTGACCAGAGTGCCT AGACCTGCCGAACTGGCCCCTCTGTGTGGCAGAAGAGGCCTGAGAACCGA CATCGACGCCACCTGTACCCCCAGAAGGGCCAGCAGCAATCAGCGGGGCC TGAATCAGATCTGGAACGTGAAGAAACAGAGCGTGTACCTGATGAACCTG AGAAAGAGCGGCACCCTGGGCCACCCTGGAAGCCTGGATGAGACAACCTA CGAGCGGCTGGCCGAGGAAACCCTGGATTCCCTGGCCGAGTTCTTCGAGG ACCTGGCCGACAAGCCCTACACCTTCGAGGATTACGACGTGTCCTTCGGC AGCGGCGTGCTGACAGTGAAGCTGGGCGGAGATCTGGGCACCTACGTGAT CAACAAGCAGACCCCCAACAAACAGATCTGGCTGAGCAGCCCCAGCAGCG GCCCCAAGAGATACGATTGGACCGGCAAGAACTGGGTGTTCAGCCACGAC GGCGTGTCCCTGCATGAGCTGCTGGCTGCCGAGCTGACCAAGGCCCTGAA AACAAAGCTGGACCTGAGCTGGCTGGCCTACAGCGGCAAAGATGCCATCG ATATCCCCAGCCCCGTTTTAAGGACATTAAAAGCTATCAGGCCAAGACCC CAGCTTCATTATGCAGCTGAGGTCTGTTTTTTGTTGTTGTTGTTGTTTAT TTTTTTTATTCCTGCTTTTGAGGACAGTTGGGCTATGTGTCACAGCTCTG TAGAAAGAATGTGTTGCCTCCTACCTTGCCCCCAAGTTCTGATTTTTAAT TTCTATGGAAGATTTTTTGGATTGTCGGATTTCCTCCCTCACATGATACC CCTTATCTTTTATAATGTCTTATGCCTATACCTGAATATAACAACCTTTA AAAAAGCAAAATAATAAGAAGGAAAAATTCCAGGAGGGAAAATGAATTGT CTTCACTCTTCATTCTTTGAAGGATTTACTGCAAGAAGTACATGAAGAGC AGCTGGTCAACCTGCTCACTGTTCTATCTCCAAATGAGACACATTAAAGG GTAGCCTACAAATGTTTTCAGGCTTCTTTCAAAGTGTAAGCACTTCTGAG CTCTTTAGCATTGAAGTGTCGAAAGCAACTCACACGGGAAGATCATTTCT TATTTGTGCTCTGTGACTGCCAAGGTGTGGCCTGCACTGGGTTGTCCAGG GAGACATGCATCTAGTGCTGTTTCTCCCACATATTCACATACGTGTCTGT GTGTATATATATTTTTTCAATTTAAAGGTTAGTATGGAATCAGCTGCTAC AAGAATGCAAAAAATCTTCCAAAGACAAGAAAAGAGGAAAAAAAGCCGTT TTCATGAGCTGAGTGATGTAGCGTAACAAACAAAATCATGGAGCTGAGGA GGTGCCTTGTAAACATGAAGGGGCAGATAAAGGAAGGAGATACTCATGTT GATAAAGAGAGCCCTGGTCCTAGACATAGTTCAGCCACAAAGTAGTTGTC CCTTTGTGGACAAGTTTCCCAAATTCCCTGGACCTCTGCTTCCCCATCTG TTAAATGAGAGAATAGAGTATGGTTGATTCCCAGCATTCAGTGGTCCTGT CAAGCAACCTAACAGGCTAGTTCTAATTCCCTATTGGGTAGATGAGGGGA TGACAAAGAACAGTTTTTAAGCTATATAGGAAACATTGTTATTGGTGTTG CCCTATCGTGATTTCAGTTGAATTCATGTGAAAATAATAGCCATCCTTGG CCTGGCGCGGTGGCTCACACCTGTAATCCCAGCACTTTTGGAGGCCAAGG TGGGTGGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGA TGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCATGATGGC AGGTGCCTGTAATCCCAGCTACTTGGGAGGCTGAAGCGGAAGAATCGCTT GAACCCAGAGGTGGAGGTTGCAGTGAGCCGAGATCGTGCCATTGCACTGT AACCTGGGTGACTGAGCAAAACTCTGTCTCAAAATAATAATAACAATATA ATAATAATAATAGCCATCCTTTATIGTACCCITACTGGGTTAATCGTATT ATACCACATTACCTCATTITAATTITTACTGACCTGCACTTTATACAAAG CAACAAGCCTCCAGGACATTAAAATTCATGCAAAGTTATGCTCATGTTAT ATTATTTTCTTACTTAAAGAAGGATTTATTAGTGGCTGGGCATGGTGGCG TGCACCTGTAATCCCAGGTACTCAGGAGGCTGAGACGGGAGAATTGCTTG ACCCCAGGCGGAGGAGGTTACAGTGAGTCGAGATCGTACCTGAGCGACAG AGCGAGACTCCGTCTCAAAAAAAAAAAAAAGGAGGGTTTATTAATGAGAA GTTTGGTCGACTAGAGCGGCCGCTTCGAGCAGACATGATAAGATACATTG ATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATT TGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAA TAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGG GGGAGATGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGT A - In some embodiments, the nucleic acid is a plasmid. In some embodiments, the nucleic acid comprises or consists of the sequence of SEQ ID NO 5.
-
Exemplary plasmid sequence (SEQ ID NO: 5) CTGCAGGGGGGGGGGGGGGGGGGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAA AGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACT CCATCACTAGGGGTTCCTCAGATCTTACCCCCTGCCCCCCACAGCTCCTCTCCTGTGCCTTGTTTCCCAGCCATG CGTTCTCCTCTATAAATACCCGCTCTGGTATTTGGGGTTGGCAGCTGTTGCTGCCAGGGAGATGGTTGGGTTGAC ATGCGGCTCCTGACAAAACACAAACCCCTGGTGTGTGTGGGCGTGGGTGGTGTGAGTAGGGGGATGAATCAGGGA GGGGGCGGGGGACCCAGGGGGCAGGAGCCACACAAAGTCTGTGCGGGGGTGGGAGCGCACATAGCAATTGGAAAC TGAAAGCTTATCAGACCCTTTCTGGAAATCAGCCCACTGTTTATAAACTTGAGGCCCCACCCTCGAGATAACCAG GGCTGAAAGAGGCCCGCCTGGGGGCTGGAGACATGCTTGCTGCCTGCCCTGGCGAAGGATTGGCAGGCTTGCCCG TCACAGGACCCCCGCTGGCTGACTCAGGGGCGCAGGCCTCTTGCGGGGGAGCTGGCCTCCCCGCCCCCACGGCCA CGGGCCGCCCTTTCCTGGCAGGACAGCGGGATCTTGCAGCTGTCAGGGGAGGGGAGGCGGGGGCTGATGTCAGGA GGGATACAAATAGTGCCGACGGCTGGGGGCCCTGTCTCCCCTCGCCGCATCCACTCTCCGGCCGGCCGCCTGTCC GCCGCCTCCTCCGTGCGCCCGCCAGCCTCGCCCGCGCCGTCACCGTGAGGCACTGGGCAGGTAAGTATCAAAGTA TCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCT GATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACAGGCTAGCCTCGAGAATTCACGCGTG GTACCTCTAGAGTCGACCGATATCACTAGTGCCACCATGTGGACACTGGGGAGAAGGGCCGTGGCTGGACTGCTG GCTTCTCCATCTCCAGCCCAGGCCCAGACCCTGACCAGAGTGCCTAGACCTGCCGAACTGGCCCCTCTGTGTGGC AGAAGAGGCCTGAGAACCGACATCGACGCCACCTGTACCCCCAGAAGGGCCAGCAGCAATCAGCGGGGCCTGAAT CAGATCTGGAACGTGAAGAAACAGAGCGTGTACCTGATGAACCTGAGAAAGAGCGGCACCCTGGGCCACCCTGGA AGCCTGGATGAGACAACCTACGAGCGGCTGGCCGAGGAAACCCTGGATTCCCTGGCCGAGTTCTTCGAGGACCTG GCCGACAAGCCCTACACCTTCGAGGATTACGACGTGTCCTTCGGCAGCGGCGTGCTGACAGTGAAGCTGGGCGGA GATCTGGGCACCTACGTGATCAACAAGCAGACCCCCAACAAACAGATCTGGCTGAGCAGCCCCAGCAGCGGCCCC AAGAGATACGATTGGACCGGCAAGAACTGGGTGTTCAGCCACGACGGCGTGTCCCTGCATGAGCTGCTGGCTGCC GAGCTGACCAAGGCCCTGAAAACAAAGCTGGACCTGAGCTGGCTGGCCTACAGCGGCAAAGATGCCATCGATATC CCCAGCCCCGTTTTAAGGACATTAAAAGCTATCAGGCCAAGACCCCAGCTTCATTATGCAGCTGAGGTCTGTTTT TTGTTGTTGTTGTTGTTTATTTTTTTTATTCCTGCTTTTGAGGACAGTTGGGCTATGTGTCACAGCTCTGTAGAA AGAATGTGTTGCCTCCTACCTTGCCCCCAAGTTCTGATTTTTAATTTCTATGGAAGATTTTTTGGATTGTCGGAT TTCCTCCCTCACATGATACCCCTTATCTTTTATAATGTCTTATGCCTATACCTGAATATAACAACCTTTAAAAAA GCAAAATAATAAGAAGGAAAAATTCCAGGAGGGAAAATGAATTGTCTTCACTCTTCATTCTTTGAAGGATTTACT GCAAGAAGTACATGAAGAGCAGCTGGTCAACCTGCTCACTGTTCTATCTCCAAATGAGACACATTAAAGGGTAGC CTACAAATGTTTTCAGGCTTCTTTCAAAGTGTAAGCACTTCTGAGCTCTTTAGCATTGAAGTGTCGAAAGCAACT CACACGGGAAGATCATTTCTTATTTGTGCTCTGTGACTGCCAAGGTGTGGCCTGCACTGGGTTGTCCAGGGAGAC ATGCATCTAGTGCTGTTTCTCCCACATATTCACATACGTGTCTGTGTGTATATATATTTTTTCAATTTAAAGGTT AGTATGGAATCAGCTGCTACAAGAATGCAAAAAATCTTCCAAAGACAAGAAAAGAGGAAAAAAAGCCGTTTTCAT GAGCTGAGTGATGTAGCGTAACAAACAAAATCATGGAGCTGAGGAGGTGCCTTGTAAACATGAAGGGGCAGATAA AGGAAGGAGATACTCATGTTGATAAAGAGAGCCCTGGTCCTAGACATAGTTCAGCCACAAAGTAGTTGTCCCTTT GTGGACAAGTTTCCCAAATTCCCTGGACCTCTGCTTCCCCATCTGTTAAATGAGAGAATAGAGTATGGTTGATTC CCAGCATTCAGTGGTCCTGTCAAGCAACCTAACAGGCTAGTTCTAATTCCCTATTGGGTAGATGAGGGGATGACA AAGAACAGTTTTTAAGCTATATAGGAAACATTGTTATTGGTGTTGCCCTATCGTGATTTCAGTTGAATTCATGTG AAAATAATAGCCATCCTTGGCCTGGCGCGGTGGCTCACACCTGTAATCCCAGCACTTTTGGAGGCCAAGGTGGGT GGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGATGAAACCCCGTCTCTACTAAAAATACAAAA AATTAGCCGGGCATGATGGCAGGTGCCTGTAATCCCAGCTACTTGGGAGGCTGAAGCGGAAGAATCGCTTGAACC CAGAGGTGGAGGTTGCAGTGAGCCGAGATCGTGCCATTGCACTGTAACCTGGGTGACTGAGCAAAACTCTGTCTC AAAATAATAATAACAATATAATAATAATAATAGCCATCCTTTATTGTACCCTTACTGGGTTAATCGTATTATACC ACATTACCTCATTTTAATTTTTACTGACCTGCACTTTATACAAAGCAACAAGCCTCCAGGACATTAAAATTCATG CAAAGTTATGCTCATGTTATATTATTTTCTTACTTAAAGAAGGATTTATTAGTGGCTGGGCATGGTGGCGTGCAC CTGTAATCCCAGGTACTCAGGAGGCTGAGACGGGAGAATTGCTTGACCCCAGGCGGAGGAGGTTACAGTGAGTCG AGATCGTACCTGAGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAGGAGGGTTTATTAATGAGAAGTTTG GTCGACTAGAGCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGC AGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAAC AAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGATGTGGGAGGTTTTTTAAAGCAAGT AAAACCTCTACAAATGTGGTAAAATCGATAAGGATCTAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTG CGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTG AGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACCCCCCCCCCCCCCCCCCTGCAGCCTGGCGTAATAGCGAAGAG GCCCGCACCGATCGCCCTTCCCAACAGTTGCGTAGCCTGAATGGCGAATGGCGCGACGCGCCCTGTAGCGGCGCA TTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTC GCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGG TTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCG CCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGA ACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAA AATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTACAATTTCCTGATGCGGTATT TTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCAT AGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTT ACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGAC GAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCA CTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGA GACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCC TTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTG AAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCC CCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCG GGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGC ATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACT TACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCC TTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGG CAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGG AGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAG CCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCT ACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGC ATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGA TCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAG ACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAA AACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCA GCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCAC CGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGT TGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCT TGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGGGA GAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACG CCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGG GGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACA TGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCC GCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCC CCGCGCGTTGGCCGATTCATTAATGCAGGG - In some embodiments, the nucleic acid is a recombinant adeno-associated virus (rAAV) vector. Exemplary rAAV nucleic acid vectors useful according to the disclosure include single-stranded (ss) or self-complementary (sc) AAV nucleic acid vectors.
- In some embodiments, a recombinant rAAV particle comprises (or packages) a nucleic acid vector that comprises an expression construct, such as a single-stranded (ss) or self-complementary (sc) AAV nucleic acid vector. In some embodiments, the nucleic acid vector comprises an expression construct comprising FXN coding sequence (e.g., a human FXN coding sequence) and a
truncated FXN 3′ UTR (e.g., a truncatedhuman FXN 3′ UTR) operably linked to a promoter (e.g., a Desmin promoter, a CBA promoter, a hFXNPro, or other promoter) and is flanked by regions comprising inverted terminal repeat (ITR) sequences (e.g., wild-type ITR sequences or engineered ITR sequences). In some embodiments, the nucleic acid is encapsidated by a viral capsid. - Accordingly, in some embodiments, a rAAV particle comprises a viral capsid and a nucleic acid vector as described herein, which is encapsidated by the viral capsid. In some embodiments, the viral capsid comprises 60 capsid protein subunits comprising VP1, VP2 and VP3. In some embodiments, the VP1, VP2, and VP3 subunits are present in the capsid at a ratio of approximately 1:1:10, respectively.
- The ITR sequences of a nucleic acid or nucleic acid vector described herein can be derived from any AAV serotype (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11,12, or 13) or can be derived from more than one serotype. In some embodiments of the nucleic acid or nucleic acid vector provided herein, the ITR sequences are derived from AAV2. ITR sequences and plasmids containing ITR sequences are known in the art and commercially available (see, e.g., products and services available from Vector Biolabs, Philadelphia, Pa.; Cellbiolabs, San Diego, Calif.; Agilent Technologies, Santa Clara, Calif.; and Addgene, Cambridge, Mass.; and Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Kessler P D, Podsakoff G M, Chen X, McQuiston S A, Colosi P C, Matelis L A, Kurtzman G J, Byrne B J. Proc Natl Acad Sci USA. 1996 Nov. 26; 93(24):14082-7; and Curtis A. Machida. Methods in Molecular Medicine™. Viral Vectors for Gene Therapy Methods and Protocols. 10.1385/1-59259-304-6:201© Humana Press Inc. 2003. Chapter 10. Targeted Integration by Adeno-Associated Virus. Matthew D. Weitzman, Samuel M. Young Jr., Toni Cathomen and Richard Jude Samulski; U.S. Pat. Nos. 5,139,941 and 5,962,313, all of which are incorporated herein by reference).
- In some embodiments, the nucleic acid or nucleic acid vector comprises a pTR-UF-11 plasmid backbone, which is a plasmid that contains AAV2 ITRs, or a nucleic acid region of the pTR-UF-11 plasmid that comprises the ITRs. This plasmid is commercially available from the American Type Culture Collection (ATCC MBA-331). One or more genes of interest (for example encoding a therapeutic protein) under the control of a promoter of interest (for example a Desmin promoter or derivative thereof described in this application) can be inserted in between the ITRs in one these or other plasmids containing AAV ITRs. These can be used as described in this application to produce a rAAV particle encapsidating a rAAV nucleic acid comprising ITRs flanking a gene of interest under the control of a promoter of interest.
- Genebank reference numbers for sequences of
AAV serotypes - In some embodiments, the expression construct is no more than 7 kilobases, no more than 6 kilobases, no more than 5 kilobases, no more than 4 kilobases, or no more than 3 kilobases in size. In some embodiments, the expression construct is between 4 and 7 kilobases in size.
- In some embodiments, the expression construct comprises one or more regions comprising a sequence that facilitates expression of the FXN coding sequence, e.g., expression control sequences operably linked to the FXN coding sequence. Non-limiting examples of expression control sequences include promoters, insulators, silencers, response elements, introns, enhancers, initiation sites, termination signals, and poly(A) tails. Any combination of such control sequences is contemplated herein (e.g., a promoter and an enhancer). In some embodiments, the promoter is a Desmin promoter as described herein. In some embodiments, the expression construct contains a splice donor/acceptor site, such as between the promoter and the FXN coding sequence.
- To achieve appropriate expression levels of FXN, any of a number of promoters suitable for use in the selected host cell may be employed. The promoter may be, for example, a constitutive promoter, tissue-specific promoter, inducible promoter, or a synthetic promoter.
- For example, constitutive promoters of different strengths can be used. A nucleic acid vector described herein may include one or more constitutive promoters, such as viral promoters or promoters from mammalian genes that are generally active in promoting transcription. Non-limiting examples of constitutive viral promoters include the Herpes Simplex virus (HSV), thymidine kinase (TK), Rous Sarcoma Virus (RSV), Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV), Ad E1A and cytomegalovirus (CMV) promoters. Non-limiting examples of constitutive mammalian promoters include various housekeeping gene promoters, as exemplified by the β-actin promoter (e.g., chicken β-actin promoter) and human elongation factor-1α (EF-1α) promoter.
- Inducible promoters and/or regulatory elements may also be contemplated for achieving appropriate expression levels of FXN. Non-limiting examples of suitable inducible promoters include those from genes such as cytochrome P450 genes, heat shock protein genes, metallothionein genes, and hormone-inducible genes, such as the estrogen gene promoter. Another example of an inducible promoter is the tetVP16 promoter that is responsive to tetracycline.
- Tissue-specific promoters and/or regulatory elements are also contemplated herein. Non-limiting examples of such promoters that may be used include hematopoietic stem cell-specific promoters.
- Synthetic promoters are also contemplated herein. A synthetic promoter may comprise, for example, regions of known promoters, regulatory elements, transcription factor binding sites, enhancer elements, repressor elements, and the like.
- Although the use of AAV has advanced in recent years, gene transfer still faces some obstacles. For example, tissue specific targeting to deliver the gene to affected organs or to avoid toxicity remains a challenge. High levels of over-expression driven by a strong promoter can lead to toxicity in vitro. In this context, organ specificity of different promoters can be taken advantage of to achieve sufficient gene delivery to target organs while avoiding complications related to administration of high doses. In some embodiments, identification of the most efficient and safe promoter element for the transcriptional control of the FXN transgene can be used to correct FXN deficiency in the heart, CNS and in the pancreatic islet cells. Thus, in some embodiments, the promoter in the disclosed nucleic acid is a human Desmin promoter or a derivative thereof. The Desmin promoter is a tissue-restricted promoter for cardiac muscle and neurons. The Desmin promoter element is a derivative of the Desmin gene control element, which contains additional transcriptional control elements to augment expression. In some embodiments, the promoter in the disclosed nucleic acid is the chicken β-actin (CBA) promoter. In some embodiments, the CBA promoter is a constitutive element made up of the cytomegalovirus (CMV) immediate early enhancer element, the beta-actin promoter and globin intron. In some embodiments, the CBA promoter allows targeting of muscle, neurons and the pancreas for FXN transgene delivery. In some embodiments, the promoter in the disclosed nucleic acid is the endogenous frataxin promoter (FxP), hFXNPro, which has been mapped to encompass a 1 kb region 5′ to the frataxin transcriptional start site. In some embodiments, the promoter in the disclosed nucleic acid is the endogenous frataxin promoter (FxP), hFXNPro, which has been mapped to encompass a 1.220 kb region 5′ to the frataxin transcriptional start site. In some embodiments, no remote enhancer elements are required, and all the necessary transcriptional control and tissue restricted activity are conferred by the frataxin promoter. However, additional regulatory sequences can be used in some embodiments. In some embodiments, the CBA promoter and the hFXNPro allow targeting of the pancreatic islet cells for FXN gene delivery. In some embodiments, the nucleic acid is a plasmid (e.g., a circular nucleic acid comprising one or more of an origin of replication, a selectable marker, and a reporter gene). In some embodiments, a nucleic acid described herein, such as a plasmid, may also contain marker or reporter genes, e.g., LacZ or a fluorescent protein, and an origin of replication. In some embodiments, the plasmid is transfected into a producer cell that produces AAV particles containing the expression construct (e.g., the expression construct that was included in the plasmid that was used to produce the nucleic acid that was encapsidated by the rAAV particles).
- The rAAV particle may be of any AAV serotype (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13), including any derivative (including non-naturally occurring variants of a serotype) or pseudotype. In some embodiments, the rAAV particle is an AAV9 particle, which may be pseudotyped with AAV2 ITRs. Non-limiting examples of derivatives and pseudotypes include AAV2-AAV3 hybrid, AAVrh.10, AAVhu.14, AAV3a/3b, AAVrh32.33, AAV-HSC15, AAV-HSC17, AAVhu.37, AAVrh.8, CHt-P6, AAV2.5, AAV6.2, AAV2i8, AAV-HSC15/17, AAVM41, AAV9.45, AAV6(Y445F/Y731F), AAV2.5T, AAV-HAE1/2, AAV clone 32/83, AAVShH10, AAV2 (Y->F), AAV8 (Y733F), AAV2.15, AAV2.4, AAVM41, and AAVr3.45. Such AAV serotypes and derivatives/pseudotypes, and methods of producing such derivatives/pseudotypes are known in the art (see, e.g., Mol Ther. 2012 April; 20(4):699-708. doi: 10.1038/mt.2011.287. Epub 2012 Jan. 24. The AAV vector toolkit: poised at the clinical crossroads. Asokan A1, Schaffer D V, Samulski R J.). In some embodiments, the rAAV particle is a pseudotyped rAAV particle, which comprises (a) a nucleic acid vector comprising ITRs from one serotype (e.g., AAV2) and (b) a capsid comprised of capsid proteins derived from another serotype (e.g., AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10). Methods for producing and using pseudotyped rAAV vectors are known in the art (see, e.g., Duan et al., J. Virol., 75:7662-7671, 2001; Halbert et al., J. Virol., 74:1524-1532, 2000; Zolotukhin et al., Methods, 28:158-167, 2002; and Auricchio et al., Hum. Molec. Genet., 10:3075-3081, 2001).
- Methods of producing rAAV particles and nucleic acid vectors are also known in the art and commercially available (see, e.g., Zolotukhin et al., Production and purification of
serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167; and U.S. Patent Publication Numbers US20070015238 and US20120322861, which are incorporated herein by reference; and plasmids and kits available from ATCC and Cell Biolabs, Inc.). For example, the nucleic acid vector (e.g., as a plasmid) may be combined with one or more helper plasmids, e.g., that contain a rep gene (e.g., encoding Rep78, Rep68, Rep52 and Rep40) and a cap gene (encoding VP1, VP2, and VP3), and transfected into a producer cell line such that the rAAV particle can be packaged and subsequently purified. - In some embodiments, the packaging is performed in a helper cell or producer cell, such as a mammalian cell or an insect cell. Exemplary mammalian cells include, but are not limited to, HEK293 cells, COS cells, HeLa cells, BHK cells, or CHO cells (see, e.g., ATCC® CRL-1573™, ATCC® CRL-1651™, ATCC® CRL-1650™, ATCC® CCL-2, ATCC® CCL-10™, or ATCC® CCL-61™). Exemplary insect cells include, but are not limited to Sf9 cells (see, e.g., ATCC® CRL-1711™). The helper cell may comprises rep and/or cap genes that encode the Rep protein and/or Cap proteins for use in a method described herein. In some embodiments, the packaging is performed in vitro.
- In some embodiments, the one or more helper plasmids includes a first helper plasmid comprising a rep gene and a cap gene and a second helper plasmid comprising other genes that assist in AAV production, such as a E1a gene, a E1b gene, a E4 gene, a E2a gene, and a VA gene. In some embodiments, the rep gene is a rep gene derived from AAV2 and the cap gene is derived from AAV5. Helper plasmids, and methods of making such plasmids, are known in the art and commercially available (see, e.g., pDF6, pRep, pDM, pDG, pDP1rs, pDP2rs, pDP3rs, pDP4rs, pDP5rs, pDP6rs, pDG(R484E/R585E), and pDP8.ape plasmids from PlasmidFactory, Bielefeld, Germany; other products and services available from Vector Biolabs, Philadelphia, Pa.; Cellbiolabs, San Diego, Calif.; Agilent Technologies, Santa Clara, Calif.; and Addgene, Cambridge, Mass.; pxx6; Grimm et al. (1998), Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors, Human Gene Therapy, Vol. 9, 2745-2760; Kern, A. et al. (2003), Identification of a Heparin-Binding Motif on Adeno-Associated Virus Type 2 Capsids, Journal of Virology, Vol. 77, 11072-11081; Grimm et al. (2003), Helper Virus-Free, Optically Controllable, and Two-Plasmid-Based Production of Adeno-associated Virus Vectors of Serotypes 1 to 6, Molecular Therapy, Vol. 7, 839-850; Kronenberg et al. (2005), A Conformational Change in the Adeno-Associated Virus Type 2 Capsid Leads to the Exposure of Hidden VP1 N Termini, Journal of Virology, Vol. 79, 5296-5303; and Moullier, P. and Snyder, R. O. (2008), International efforts for recombinant adenoassociated viral vector reference standards, Molecular Therapy, Vol. 16, 1185-1188).
- An exemplary, non-limiting, rAAV particle production method is described next. One or more helper plasmids are produced or obtained, which comprise rep and cap ORFs for the desired AAV serotype and the adenoviral VA, E2A (DBP), and E4 genes under the transcriptional control of their native promoters. HEK293 cells (available from ATCC®) are transfected via CaPO4-mediated transfection, lipids or polymeric molecules such as Polyethylenimine (PEI) with the helper plasmid(s) and a plasmid containing a nucleic acid vector described herein. Alternatively, in another example, Sf9-based producer stable cell lines are infected with a single recombinant baculovirus containing the nucleic acid vector. As a further alternative, in another example HEK293 or BHK cell lines are infected with a HSV containing the nucleic acid vector and optionally one or more helper HSVs containing rep and cap ORFs as described herein and the adenoviral VA, E2A (DBP), and E4 genes under the transcriptional control of their native promoters. The HEK293, BHK, or Sf9 cells are then incubated for at least 60 hours to allow for rAAV particle production. The rAAV particles can then be purified using any method known the art or described herein, e.g., by iodixanol step gradient, CsCl gradient, chromatography, or polyethylene glycol (PEG) precipitation.
- The disclosure also contemplates host cells that comprise at least one of the disclosed rAAV particles, expression constructs, or nucleic acid vectors. Such host cells include mammalian host cells, with human host cells being preferred, and may be either isolated, in cell or tissue culture. In the case of genetically modified animal models (e.g., a mouse), the transformed host cells may be comprised within the body of a non-human animal itself.
- Aspects of the disclosure relate to compositions comprising rAAV particles or nucleic acids described herein. In some embodiments, rAAV particles described herein are added to a composition, e.g., a pharmaceutical composition.
- In some embodiments, the composition comprises a pharmaceutically acceptable carrier. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the rAAV particle is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum oil such as mineral oil, vegetable oil such as peanut oil, soybean oil, and sesame oil, animal oil, or oil of synthetic origin. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers. Non-limiting examples of pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline, syrup, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, polyacrylic acids, lubricating agents (such as talc, magnesium stearate, and mineral oil), wetting agents, emulsifying agents, suspending agents, preserving agents (such as methyl-, ethyl-, and propyl-hydroxy-benzoates), and pH adjusting agents (such as inorganic and organic acids and bases). Other examples of carriers include phosphate buffered saline, HEPES-buffered saline, and water for injection, any of which may be optionally combined with one or more of calcium chloride dihydrate, disodium phosphate anhydrous, magnesium chloride hexahydrate, potassium chloride, potassium dihydrogen phosphate, sodium chloride, or sucrose. Other examples of carriers that might be used include saline (e.g., sterilized, pyrogen-free saline), saline buffers (e.g., citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (for example, serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. USP grade carriers and excipients are particularly useful for delivery of rAAV particles to human subjects. Such compositions may further optionally comprise a liposome, a lipid, a lipid complex, a microsphere, a microparticle, a nanosphere, or a nanoparticle, or may be otherwise formulated for administration to the cells, tissues, organs, or body of a subject in need thereof. Methods for making such compositions are well known and can be found in, for example, Remington: The Science and Practice of Pharmacy, 22nd edition, Pharmaceutical Press, 2012.
- Typically, such compositions may contain at least about 0.1% of the therapeutic agent (e.g., rAAV particle) or more, although the percentage of the active ingredient(s) may, of course, be varied and may conveniently be between about 1 or 2% and about 70% or 80% or more of the weight or volume of the total formulation. Naturally, the amount of therapeutic agent(s) (e.g., rAAV particle) in each therapeutically-useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.
- In some embodiments, a composition described herein may be administered to a subject in need thereof, such as a subject having Friedreich's ataxia. In some embodiments, a method described herein may comprise administering a composition comprising rAAV particles as described herein to a subject in need thereof. In some embodiments, the subject is a human subject. In some embodiments, the subject has or is suspected of having a disease that may be treated with gene therapy, such as Friedreich's ataxia.
- Aspects of the disclosure relate to treatment of Friedreich's ataxia. In some embodiments, the method comprises administering a therapeutically effective amount of an rAAV particle or a composition as described herein to a subject having Friedreich's ataxia.
- To “treat” a disease as the term is used herein, means to reduce the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject. The compositions described above or elsewhere herein are typically administered to a subject in an effective amount, that is, an amount capable of producing a desirable result. The desirable result will depend upon the active agent being administered. For example, an effective amount of rAAV particles may be an amount of the particles that are capable of transferring an expression construct to a host organ, tissue, or cell. A therapeutically acceptable amount may be an amount that is capable of treating a disease, e.g., Friedreich's ataxia. As is well known in the medical and veterinary arts, dosage for any one subject depends on many factors, including the subject's size, body surface area, age, the particular composition to be administered, the active ingredient(s) in the composition, time and route of administration, general health, and other drugs being administered concurrently.
- The rAAV particle or nucleic acid vector may be delivered in the form of a composition, such as a composition comprising the active ingredient, such as a rAAV particle described herein, and a pharmaceutically acceptable carrier as described herein. The rAAV particles or nucleic acid vectors may be prepared in a variety of compositions, and may also be formulated in appropriate pharmaceutical vehicles for administration to human or animal subjects.
- In some embodiments, the number of rAAV particles administered to a subject may be on the order ranging from 106 to 1014 particles/ml or 103 to 1015 particles/ml, or any values therebetween for either range, such as for example, about 106, 107, 108, 109, 1010, 1011, 1012, 1013, or 1014 particles/ml. In one embodiment, rAAV particles of higher than 1013 particles/ml are be administered. In some embodiments, the number of rAAV particles administered to a subject may be on the order ranging from 106 to 1014 vector genomes(vgs)/ml or 103 to 1015 vgs/ml, or any values therebetween for either range, such as for example, about 106, 107, 108, 109, 1010, 1011, 1012, 1013, or 1014 vgs/ml. In one embodiment, rAAV particles of higher than 1013 vgs/ml are be administered. The rAAV particles can be administered as a single dose, or divided into two or more administrations as may be required to achieve therapy of the particular disease or disorder being treated. In some embodiments, 0.0001 ml to 10 mls are delivered to a subject. In some embodiments, the number of rAAV particles administered to a subject may be on the order ranging from 106-1014 vg/kg, or any values therebetween, such as for example, about 106, 107, 108, 109, 1010, 1011, 1012, 1013, or 1014 vgs/mg. In some embodiments, the number of rAAV particles administered to a subject may be on the order ranging from 1012-1014 vgs/kg.
- If desired, rAAV particles may be administered in combination with other agents as well, such as, e.g., proteins or polypeptides or various pharmaceutically-active agents, including one or more systemic or topical administrations of therapeutic polypeptides, biologically active fragments, or variants thereof. In fact, there is virtually no limit to other components that may also be included, given that the additional agents do not cause a significant adverse effect upon contact with the target cells or host tissues. The rAAV particles may thus be delivered along with various other agents as required in the particular instance. Such compositions may be purified from host cells or other biological sources, or alternatively may be chemically synthesized.
- In certain circumstances it will be desirable to deliver the rAAV particles in suitably formulated pharmaceutical compositions disclosed herein either subcutaneously, intraocularly, intravitreally, subretinally, parenterally, intravenously (IV), intracerebro-ventricularly, intramuscularly, intrathecally (IT), intracisternally, orally, intraperitoneally, by oral or nasal inhalation, or by direct injection to one or more cells, tissues, or organs by direct injection. In some embodiments, the administration is a route suitable for systemic delivery, such as by intravenous injection. In some embodiments, “administering” or “administration” means providing a material to a subject in a manner that is pharmacologically useful.
- To address the systemic manifestations of FRDA, approaches to transfer AAV vectors globally that target both the neurological and cardiac impairment may be needed. Although IV dosing is an advantageous route to transduce the heart, it does not have high translational feasibility for CNS disorders because of the high dose requirement, high distribution to peripheral tissues and reduced efficiency for CNS transduction (Schuster, D. et al., Front Neuronat., 8:42, 2014). However, intrathecal (IT) dosing of AAV9 (e.g., via lumbar cistern or cisterna magna) is a viable, clinically relevant option for global CNS gene delivery (Gray, S. et al., Gene Ther, 20(4):450-9, 2013; Federici, T. et al., Gene Ther, 19(8):852, 2012; Snyder, B. et al., Hum Gene Ther, 22(9):1129, 2011). A method of treating subjects with FRDA using a combination of different routes of administration (e.g., IV and IT), by transduction of cardiac muscle, pancreas (e.g., pancreatic islet cells), and CNS (e.g., dorsal root ganglia, and the cerebellum) is contemplated herein. Thus, in some embodiments, rAAV particles or compositions comprising rAAV particles that comprise (or package) FXN transgene are administered via intravenous (IV) injection. In some embodiments, rAAV particles or compositions comprising rAAV particles that comprise (or package) FXN transgene are administered via intrathecal (IT) injection. In some embodiments, rAAV particles or compositions comprising rAAV particles that comprise (or package) FXN transgene are administered via intracisternal injection, so as to deliver the rAAV particles within a cistern of the brain. In some embodiments, rAAV particles or compositions comprising rAAV particles that package FXN transgene are administered via both an intravenous injection and an intrathecal injection, or via an intravenous injection and an intracisternal injection.
- In some embodiments, more than two (e.g., three, or four) of the above described routes of administration are utilized.
- In some embodiments, the ratio of rAAV particles administered to the subject via intravenous injection to rAAV particles administered to the subject via intrathecal injection is in the range of 10:1 to 1:10 (e.g., 10:1, 8:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:5, 1:8, 1:10), or 50:1 to 1:50 (e.g., 50:1, 40:1, 25:1, 30:1, 10:1, 1:1, 1:10, 1:30, 1:25, 1:40, 1:50), or 100:1 to 1:100 (e.g., 100:1, 80:1, 50:1, 10:1, 1:1, 1:10, 1:50, 1:80, 1:100), or 1000:1 to 1:1000 (e.g., 1000:1, 800:1, 500:1, 100:1, 1:1, 1:100, 1:500, 1:800, 1:1000). In some embodiments, the ratio of rAAV particles administered to the subject via intravenous injection to rAAV particles administered to the subject via intracisternal injection is in the range of 10:1 to 1:10 (e.g., 10:1, 8:1, 5:1, 4:1, 2:1, 1:1, 1:2, 1:5, 1:8, 1:10), or 50:1 to 1:50 (e.g., 50:1, 40:1, 25:1, 30:1, 10:1, 1:1, 1:10, 1:30, 1:25, 1:40, 1:50), or 100:1 to 1:100 (e.g., 100:1, 80:1, 50:1, 10:1, 1:1, 1:10, 1:50, 1:80, 1:100), or 1000:1 to 1:1000 (e.g., 1000:1, 800:1, 500:1, 100:1, 1:1, 1:100, 1:500, 1:800, 1:1000). In some embodiments, the ratio of rAAV particles administered to the subject via intravenous injection to rAAV particles administered to the subject via intrathecal injection is 1:10. In some embodiments, the ratio of rAAV particles administered to the subject via intravenous injection to rAAV particles administered to the subject via intracisternal injection is 1:10. In some embodiments, compositions administered via intravenous, intrathecal, and/or intracisternal injection may have the same number of particles or viral genomes per unit volume. However, in some embodiments compositions having different titers may be used for different routes of administration. Also, different compositions having different components in addition to the viral particles may be used for different routes of administration.
- The amount of rAAV particle or nucleic acid vector compositions and time of administration of such compositions will be within the purview of the skilled artisan having benefit of the present teachings. It is likely, however, that the administration of therapeutically-effective amounts of the disclosed compositions may be achieved by a single administration, such as for example, a single injection of sufficient numbers of infectious particles to provide therapeutic benefit to the patient undergoing such treatment. Alternatively, in some circumstances, it may be desirable to provide multiple, or successive administrations of the rAAV particle compositions, either over a relatively short, or a relatively prolonged period of time, as may be determined by the medical practitioner overseeing the administration of such compositions.
- In some embodiments, when more than one route of administration is utilized, the administration of rAAV comprising FXN transgene via the two or more routes is performed simultaneously, or within 10 min of each other. In some embodiments, when more than one route of administration is utilized, the administration of rAAV comprising FXN transgene via the two or more routes is staggered, so that administration via the second route is performed 10 min, 20 min, 30 min 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 12 h, 18 h, or 24 h after the administration via the first route. In some embodiments, when more than one route of administration is utilized, the administration of rAAV comprising FXN transgene via the two or more routes is altered, so that administration via the second route replaces administration via the first route on a routine basis (e.g., for once a day schedule, administration via first route on day 1, administration via second route on
day 2, administration via first route onday 3, administration via second route on day 4, and so on). - In some embodiments, the number of rAAV particles administered to a subject may be on the order ranging from 106 to 1014 particles/mL or 103 to 1013 particles/mL, or any values therebetween for either range, such as for example, about 106, 107, 108, 109, 1010, 1011, 1012, 1013, or 1014 particles/mL. In some embodiments, rAAV particle compositions of lower than 107 particles/mL, for example lower than 103 particles/mL, are administered. In some embodiments, rAAV particle compositions of higher than 1013 particles/mL, for example higher than 1015 particles/mL, are administered. In some embodiments, the number of rAAV particles administered to a subject may be on the order ranging from 106 to 1014 vector genomes(vgs)/mL or 103 to 1015 vgs/mL, or any values there between for either range, such as for example, about 106, 107, 108, 109, 1010, 1011, 1012, 1013, or 1014 vgs/mL. In some embodiments, rAAV particle compositions of lower than 107 vgs/mL, for example lower than 103 vgs/mL, are be administered. In some embodiments, rAAV particle compositions of higher than 1013 vgs/mL, for example higher than 1015 vgs/mL, are administered. In some embodiments, 0.0001 mL to 10 mLs are delivered to a subject (e.g., via one or more routes of administration as described in this application).
- IV and IT injections are routine non-surgical procedures that are often done in an outpatient setting with minimal risk (Mattar, C. et al., FASEB J, 29(9):3876, 2015; Gray, S. et al., Gene Ther, 20(4):450-9, 2013; Federici, T. et al., Gene Ther, 19(8):852, 2012; Snyder, B. et al., Hum Gene Ther, 22(9):1129, 2011).
- The pharmaceutical forms of the rAAV particle compositions suitable for injectable use include sterile aqueous solutions or dispersions. In some embodiments, the form is sterile and fluid to the extent that easy syringability exists. In some embodiments, the form is stable under the conditions of manufacture and storage and is preserved against the contaminating action of microorganisms, such as bacteria and fungi. In some embodiments, the form is sterile. The carrier can be a solvent or dispersion medium containing, for example, water, saline, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- For administration of an injectable aqueous solution, for example, the solution may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, intravitreal, subretinal, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and the general safety and purity standards as required by, e.g., FDA Office of Biologics standards.
- Sterile injectable solutions are prepared by incorporating the rAAV particles in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization or another sterilization technique. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- The composition may include rAAV particles, either alone, or in combination with one or more additional active ingredients, which may be obtained from natural or recombinant sources or chemically synthesized.
- Toxicity and efficacy of the compositions utilized in methods of the disclosure can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD50 (the dose lethal to 50% of the population). The dose ratio between toxicity and efficacy the therapeutic index and it can be expressed as the ratio LD50/ED50. Those compositions that exhibit large therapeutic indices are preferred. While those that exhibit toxic side effects may be used, care should be taken to design a delivery system that minimizes the potential damage of such side effects. The dosage of compositions as described herein lies generally within a range that includes an ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- Aspects of the disclosure relate to methods for use with a subject, such as human or non-human primate subjects. Non-limiting examples of non-human primate subjects include macaques (e.g., cynomolgus or rhesus macaques), marmosets, tamarins, spider monkeys, owl monkeys, vervet monkeys, squirrel monkeys, baboons, gorillas, chimpanzees, and orangutans. In some embodiments, the subject is a human subject. Other exemplary subjects include domesticated animals such as dogs and cats; livestock such as horses, cattle, pigs, sheep, goats, and chickens; and other animals such as mice, rats, guinea pigs, and hamsters.
- In some embodiments, the subject has or is suspected of having a disease that may be treated with gene therapy. In some embodiments, the subject has or is suspected of having Friedreich's ataxia. Friedreich's ataxia (FRDA) is a rare inherited disease that causes degeneration of the spinal cord and peripheral nervous system. Subjects with FRDA generally have an expanded number of GAA repeats in the FXN gene. A subject generally must have both copies of the FXN with expanded repeats to develop FRDA, although about 2 percent of subjects have one copy of the FXN gene with expanded repeats and another different type of mutation in the other copy of the FXN gene. Generally, if a subject has more than 66 to more than 1,000 GAA repeats in both copies of the FXN gene, they will develop FRDA. Symptoms of FRDA include gait ataxia, loss of sensation in the extremities, loss of tendon reflexes, scoliosis, dysarthria, hearing loss, vision loss, chest pain, shortness of breath, and heart palpitations. Subjects with FRDA may also develop carbohydrate intolerance or diabetes. Subjects with fewer than 300 repeats may develop symptoms later in life than those with additional repeats. Subject having FRDA can be identified by the skilled practitioner using methods known in the art or described herein, e.g., using genetic testing, electromyogram (EMG), nerve conduction studies, electrocardiogram (ECG), echocardiogram, blood tests for elevated glucose and vitamin E, magnetic resonance imaging (MRI) or computed tomography (CT) scans, and combinations thereof.
- Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present disclosure to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference for the purposes or subject matter referenced herein.
- Friedrich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by a triplet repeat expansion in the frataxin gene (FXN), which encodes the mitochondrial protein frataxin. Deficiency in frataxin expression results in severe mitochondrial dysfunction leading to progressive gait abnormality, impaired muscle coordination, muscle weakness, hyporeflexia, dysmetria, dysarthria, and hypertrophic cardiomyopathy. Currently, there are no approved treatments for FRDA, which is the most common occurring autosomal recessive ataxia, affecting 1 in 50,000 people worldwide. Precise quantification of frataxin levels is critical for establishing the effectiveness of potential therapies. Therefore, methods that improve detection of FXN expression will facilitate the implementation of novel therapies into a clinical setting. The overall objective was to establish an approach for effective gene transfer and quantification of frataxin levels sufficient to restore mitochondrial function. Stable isotope labeling of amino acids in cell culture or in mammals (SILAC/M) is a novel and sensitive mass spectrometry based approach used herein for the quantification of frataxin levels; therefore enabling determination of required levels for correction of FXN deficiency.
- A rAAV2/9-FXN vector expressing codon optimized human FXN was generated for use in models of FRDA. rAAV2/9 means that the nucleic acid vector contained AAV2 ITRs and the capsid encapsidating the nucleic acid vector was an AAV9 capsid. A map of a non-limiting plasmid containing the FXN expression construct is shown in
FIG. 1 . The sequence of the plasmid is below. The sequence of the Desmin promoter in the plasmid is also shown (SEQ ID NO: 2, and see alsoFIG. 6 ). The frataxin gene sequence was codon-optimized using LifeTechnologies strategy using GeneOptimizer® software which calculates the optimal DNA sequence needed to encode the protein of interest (gene optimization). -
AAV plasmid with Human FXN codon-optimized coding sequence and truncated 3′ UTR driven by Desmin promoter (ITR from position 22-164, Desmin promoter from position 171-882, SD/SA from position 896-1026, CDS (codon optimized human Frataxin - hFXNco) from position 1087-2034, 3′ UTR (human FXN 3′ UTR) from position 2035-3525, polyA signal from position 3550-3771, and ITR (complement) from position 3792-3934): (SEQ ID NO: 10) 1 CTGCAGGGGG GGGGGGGGGG GGGTTGGCCA CTCCCTCTCT GCGCGCTCGC TCGCTCACTG 61 AGGCCGGGCG ACCAAAGGTC GCCCGACGCC CGGGCTTTGC CCGGGCGGCC TCAGTGAGCG 121 AGCGAGCGCG CAGAGAGGGA GTGGCCAACT CCATCACTAG GGGTTCCTCA GATCTTACCC 181 CCTGCCCCCC ACAGCTCCTC TCCTGTGCCT TGTTTCCCAG CCATGCGTTC TCCTCTATAA 241 ATACCCGCTC TGGTATTTGG GGTTGGCAGC TGTTGCTGCC AGGGAGATGG TTGGGTTGAC 301 ATGCGGCTCC TGACAAAACA CAAACCCCTG GTGTGTGTGG GCGTGGGTGG TGTGAGTAGG 361 GGGATGAATC AGGGAGGGGG CGGGGGACCC AGGGGGCAGG AGCCACACAA AGTCTGTGCG 421 GGGGTGGGAG CGCACATAGC AATTGGAAAC TGAAAGCTTA TCAGACCCTT TCTGGAAATC 481 AGCCCACTGT TTATAAACTT GAGGCCCCAC CCTCGAGATA ACCAGGGCTG AAAGAGGCCC 541 GCCTGGGGGC TGGAGACATG CTTGCTGCCT GCCCTGGCGA AGGATTGGCA GGCTTGCCCG 601 TCACAGGACC CCCGCTGGCT GACTCAGGGG CGCAGGCCTC TTGCGGGGGA GCTGGCCTCC 661 CCGCCCCCAC GGCCACGGGC CGCCCTTTCC TGGCAGGACA GCGGGATCTT GCAGCTGTCA 721 GGGGAGGGGA GGCGGGGGCT GATGTCAGGA GGGATACAAA TAGTGCCGAC GGCTGGGGGC 781 CCTGTCTCCC CTCGCCGCAT CCACTCTCCG GCCGGCCGCC TGTCCGCCGC CTCCTCCGTG 841 CGCCCGCCAG CCTCGCCCGC GCCGTCACCG TGAGGCACTG GGCAGGTAAG TATCAAAGTA 901 TCAAGGTTAC AAGACAGGTT TAAGGAGACC AATAGAAACT GGGCTTGTCG AGACAGAGAA 961 GACTCTTGCG TTTCTGATAG GCACCTATTG GTCTTACTGA CATCCACTTT GCCTTTCTCT 1021 CCACAGGCTA GCCTCGAGAA TTCACGCGTG GTACCTCTAG AGTCGACCGA TATCACTAGT 1081 GCCACCATGT GGACACTGGG GAGAAGGGCC GTGGCTGGAC TGCTGGCTTC TCCATCTCCA 1141 GCCCAGGCCC AGACCCTGAC CAGAGTGCCT AGACCTGCCG AACTGGCCCC TCTGTGTGGC 1201 AGAAGAGGCC TGAGAACCGA CATCGACGCC ACCTGTACCC CCAGAAGGGC CAGCAGCAAT 1261 CAGCGGGGCC TGAATCAGAT CTGGAACGTG AAGAAACAGA GCGTGTACCT GATGAACCTG 1321 AGAAAGAGCG GCACCCTGGG CCACCCTGGA AGCCTGGATG AGACAACCTA CGAGCGGCTG 1381 GCCGAGGAAA CCCTGGATTC CCTGGCCGAG TTCTTCGAGG ACCTGGCCGA CAAGCCCTAC 1441 ACCTTCGAGG ATTACGACGT GTCCTTCGGC AGCGGCGTGC TGACAGTGAA GCTGGGCGGA 1501 GATCTGGGCA CCTACGTGAT CAACAAGCAG ACCCCCAACA AACAGATCTG GCTGAGCAGC 1561 CCCAGCAGCG GCCCCAAGAG ATACGATTGG ACCGGCAAGA ACTGGGTGTT CAGCCACGAC 1621 GGCGTGTCCC TGCATGAGCT GCTGGCTGCC GAGCTGACCA AGGCCCTGAA AACAAAGCTG 1681 GACCTGAGCT GGCTGGCCTA CAGCGGCAAA GATGCCATCG ATATCCCCAG CCCCGTTTTA 1741 AGGACATTAA AAGCTATCAG GCCAAGACCC CAGCTTCATT ATGCAGCTGA GGTCTGTTTT 1801 TTGTTGTTGT TGTTGTTTAT TTTTTTTATT CCTGCTTTTG AGGACAGTTG GGCTATGTGT 1861 CACAGCTCTG TAGAAAGAAT GTGTTGCCTC CTACCTTGCC CCCAAGTTCT GATTTTTAAT 1921 TTCTATGGAA GATTTTTTGG ATTGTCGGAT TTCCTCCCTC ACATGATACC CCTTATCTTT 1981 TATAATGTCT TATGCCTATA CCTGAATATA ACAACCTTTA AAAAAGCAAA ATAATAAGAA 2041 GGAAAAATTC CAGGAGGGAA AATGAATTGT CTTCACTCTT CATTCTTTGA AGGATTTACT 2101 GCAAGAAGTA CATGAAGAGC AGCTGGTCAA CCTGCTCACT GTTCTATCTC CAAATGAGAC 2161 ACATTAAAGG GTAGCCTACA AATGTTTTCA GGCTTCTTTC AAAGTGTAAG CACTTCTGAG 2221 CTCTTTAGCA TTGAAGTGTC GAAAGCAACT CACACGGGAA GATCATTTCT TATTTGTGCT 2281 CTGTGACTGC CAAGGTGTGG CCTGCACTGG GTTGTCCAGG GAGACATGCA TCTAGTGCTG 2341 TTTCTCCCAC ATATTCACAT ACGTGTCTGT GTGTATATAT ATTTTTTCAA TTTAAAGGTT 2401 AGTATGGAAT CAGCTGCTAC AAGAATGCAA AAAATCTTCC AAAGACAAGA AAAGAGGAAA 2461 AAAAGCCGTT TTCATGAGCT GAGTGATGTA GCGTAACAAA CAAAATCATG GAGCTGAGGA 2521 GGTGCCTTGT AAACATGAAG GGGCAGATAA AGGAAGGAGA TACTCATGTT GATAAAGAGA 2581 GCCCTGGTCC TAGACATAGT TCAGCCACAA AGTAGTTGTC CCTTTGTGGA CAAGTTTCCC 2641 AAATTCCCTG GACCTCTGCT TCCCCATCTG TTAAATGAGA GAATAGAGTA TGGTTGATTC 2701 CCAGCATTCA GTGGTCCTGT CAAGCAACCT AACAGGCTAG TTCTAATTCC CTATTGGGTA 2761 GATGAGGGGA TGACAAAGAA CAGTTTTTAA GCTATATAGG AAACATTGTT ATTGGTGTTG 2821 CCCTATCGTG ATTTCAGTTG AATTCATGTG AAAATAATAG CCATCCTTGG CCTGGCGCGG 2881 TGGCTCACAC CTGTAATCCC AGCACTTTTG GAGGCCAAGG TGGGTGGATC ACCTGAGGTC 2941 AGGAGTTCAA GACCAGCCTG GCCAACATGA TGAAACCCCG TCTCTACTAA AAATACAAAA 3001 AATTAGCCGG GCATGATGGC AGGTGCCTGT AATCCCAGCT ACTTGGGAGG CTGAAGCGGA 3061 AGAATCGCTT GAACCCAGAG GTGGAGGTTG CAGTGAGCCG AGATCGTGCC ATTGCACTGT 3121 AACCTGGGTG ACTGAGCAAA ACTCTGTCTC AAAATAATAA TAACAATATA ATAATAATAA 3181 TAGCCATCCT TTATTGTACC CTTACTGGGT TAATCGTATT ATACCACATT ACCTCATTTT 3241 AATTTTTACT GACCTGCACT TTATACAAAG CAACAAGCCT CCAGGACATT AAAATTCATG 3301 CAAAGTTATG CTCATGTTAT ATTATTTTCT TACTTAAAGA AGGATTTATT AGTGGCTGGG 3361 CATGGTGGCG TGCACCTGTA ATCCCAGGTA CTCAGGAGGC TGAGACGGGA GAATTGCTTG 3421 ACCCCAGGCG GAGGAGGTTA CAGTGAGTCG AGATCGTACC TGAGCGACAG AGCGAGACTC 3481 CGTCTCAAAA AAAAAAAAAA GGAGGGTTTA TTAATGAGAA GTTTGGTCGA CTAGAGCGGC 3541 CGCTTCGAGC AGACATGATA AGATACATTG ATGAGTTTGG ACAAACCACA ACTAGAATGC 3601 AGTGAAAAAA ATGCTTTATT TGTGAAATTT GTGATGCTAT TGCTTTATTT GTAACCATTA 3661 TAAGCTGCAA TAAACAAGTT AACAACAACA ATTGCATTCA TTTTATGTTT CAGGTTCAGG 3721 GGGAGATGTG GGAGGTTTTT TAAAGCAAGT AAAACCTCTA CAAATGTGGT AAAATCGATA 3781 AGGATCTAGG AACCCCTAGT GATGGAGTTG GCCACTCCCT CTCTGCGCGC TCGCTCGCTC 3841 ACTGAGGCCG CCCGGGCAAA GCCCGGGCGT CGGGCGACCT TTGGTCGCCC GGCCTCAGTG 3901 AGCGAGCGAG CGCGCAGAGA GGGAGTGGCC AACCCCCCCC CCCCCCCCCC TGCAGCCTGG 3961 CGTAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGTAG CCTGAATGGC 4021 GAATGGCGCG ACGCGCCCTG TAGCGGCGCA TTAAGCGCGG CGGGTGTGGT GGTTACGCGC 4081 AGCGTGACCG CTACACTTGC CAGCGCCCTA GCGCCCGCTC CTTTCGCTTT CTTCCCTTCC 4141 TTTCTCGCCA CGTTCGCCGG CTTTCCCCGT CAAGCTCTAA ATCGGGGGCT CCCTTTAGGG 4201 TTCCGATTTA GTGCTTTACG GCACCTCGAC CCCAAAAAAC TTGATTAGGG TGATGGTTCA 4261 CGTAGTGGGC CATCGCCCTG ATAGACGGTT TTTCGCCCTT TGACGTTGGA GTCCACGTTC 4321 TTTAATAGTG GACTCTTGTT CCAAACTGGA ACAACACTCA ACCCTATCTC GGTCTATTCT 4381 TTTGATTTAT AAGGGATTTT GCCGATTTCG GCCTATTGGT TAAAAAATGA GCTGATTTAA 4441 CAAAAATTTA ACGCGAATTT TAACAAAATA TTAACGTTTA CAATTTCCTG ATGCGGTATT 4501 TTCTCCTTAC GCATCTGTGC GGTATTTCAC ACCGCATATG GTGCACTCTC AGTACAATCT 4561 GCTCTGATGC CGCATAGTTA AGCCAGCCCC GACACCCGCC AACACCCGCT GACGCGCCCT 4621 GACGGGCTTG TCTGCTCCCG GCATCCGCTT ACAGACAAGC TGTGACCGTC TCCGGGAGCT 4681 GCATGTGTCA GAGGTTTTCA CCGTCATCAC CGAAACGCGC GAGACGAAAG GGCCTCGTGA 4741 TACGCCTATT TTTATAGGTT AATGTCATGA TAATAATGGT TTCTTAGACG TCAGGTGGCA 4801 CTTTTCGGGG AAATGTGCGC GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA 4861 TGTATCCGCT CATGAGACAA TAACCCTGAT AAATGCTTCA ATAATATTGA AAAAGGAAGA 4921 GTATGAGTAT TCAACATTTC CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC 4981 CTGTTTTTGC TCACCCAGAA ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG 5041 CACGAGTGGG TTACATCGAA CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC 5101 CCGAAGAACG TTTTCCAATG ATGAGCACTT TTAAAGTTCT GCTATGTGGC GCGGTATTAT 5161 CCCGTATTGA CGCCGGGCAA GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT 5221 TGGTTGAGTA CTCACCAGTC ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT 5281 TATGCAGTGC TGCCATAACC ATGAGTGATA ACACTGCGGC CAACTTACTT CTGACAACGA 5341 TCGGAGGACC GAAGGAGCTA ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC 5401 TTGATCGTTG GGAACCGGAG CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA 5461 TGCCTGTAGC AATGGCAACA ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG 5521 CTTCCCGGCA ACAATTAATA GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC 5581 GCTCGGCCCT TCCGGCTGGC TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT 5641 CTCGCGGTAT CATTGCAGCA CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GTAGTTATCT 5701 ACACGACGGG GAGTCAGGCA ACTATGGATG AACGAAATAG ACAGATCGCT GAGATAGGTG 5761 CCTCACTGAT TAAGCATTGG TAACTGTCAG ACCAAGTTTA CTCATATATA CTTTAGATTG 5821 ATTTAAAACT TCATTTTTAA TTTAAAAGGA TCTAGGTGAA GATCCTTTTT GATAATCTCA 5881 TGACCAAAAT CCCTTAACGT GAGTTTTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA 5941 TCAAAGGATC TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA 6001 AACCACCGCT ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA 6061 AGGTAACTGG CTTCAGCAGA GCGCAGATAC CAAATACTGT CCTTCTAGTG TAGCCGTAGT 6121 TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT 6181 TACCAGTGGC TGCTGCCAGT GGCGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT 6241 AGTTACCGGA TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT 6301 TGGAGCGAAC GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCATTGA GAAAGCGCCA 6361 CGCTTCCCGA AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG 6421 AGCGCACGAG GGAGCTTCCA GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC 6481 GCCACCTCTG ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA 6541 AAAACGCCAG CAACGCGGCC TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA 6601 TGTTCTTTCC TGCGTTATCC CCTGATTCTG TGGATAACCG TATTACCGCC TTTGAGTGAG 6661 CTGATACCGC TCGCCGCAGC CGAACGACCG AGCGCAGCGA GTCAGTGAGC GAGGAAGCGG 6721 AAGAGCGCCC AATACGCAAA CCGCCTCTCC CCGCGCGTTG GCCGATTCAT TAATGCAGGG - A polypeptide translation is as follows:
-
(SEQ ID NO: 11) MWTLGRRAVAGLLASPSPAQAQTLTRVPRPAELAPLCGRRGLRTDIDATC TPRRASSNQRGLNQIWNVKKQSVYLMNLRKSGTLGHPGSLDETTYERLAE ETLDSLAEFFEDLADKPYTFEDYDVSFGSGVLTVKLGGDLGTYVINKQTP NKQIWLSSPSSGPKRYDWTGKNWVFSHDGVSLHELLAAELTKALKTKLDL SWLAYSGKDAIDIPSPVLRTLKAIRPRPQLHYAAEVCFLLLLLFIFFIPA FEDSWAMCHSSVERMCCLLPCPQVLIFNFYGRFFGLSDFLPHMIPLIFYN VLCLYLNITTFKKAK - Renal epithelial cells (REC) were isolated from control and FRDA patients, and SILAC was used to quantify AAV-mediated FXN expression in-vitro. Induced pluripotent stem cells (IPSC) were generated from the RECs, and were subsequently differentiated to cardiomyocytes and neurons. AAV-mediated correction of FXN was verified by increased mitochondrial activity including reduced iron deposition and increased aconitase function in FRDA cells. Preliminary results showed that SILAC/M was able to accurately measure endogenous and vector derived FXN expression in-vitro and in-vivo. Moreover, improvement in mitochondrial function was correlated with levels of FXN expression in vitro. These studies indicate that rAAV vectors of the present disclosure are useful to treat FRDA.
- A clinical candidate vector was designed to express frataxin. The vector contained an expression cassette with human Desmin (DES) promoter driving codon-optimized human FXN with a truncated
human FXN 3′ UTR. The expression cassette was flanked by AAV2 ITRs. The plasmid containing the expression cassette is shown inFIG. 1 and is further described in Example 1. The plasmid was used with AAV2 rep and AAV9 capsid helper plasmids to package the vector in an AAV9 capsid, resulting in rAAV2/9-FXN, which was used in all of the studies described below. - A cellular model of FRDA was developed as follows. FA2 cells are renal epithelial cells that were derived from FRDA patients (
FIG. 2A ). Induced pluripotent stem cells (IPSCs) were generated from the FA2 cells (FIG. 2B ) and were differentiated into cardiomyocytes (FIG. 2C ) and neural progenitor cells. Cardiomyocyte differentiation took about two weeks, whereas neural progenitor cell differentiation took about three weeks. - The IPSC differentiation to cardiomyocytes and progenitor cells was validated by assessing cardiac and neuronal markers. NKX2.5 and TroponinT were used as markers of cardiomyocytes. The IPSCs differentiated into cardiomyocytes expressed both markers (
FIG. 3A ). Neurofluor CDr3 was used to confirm neural progenitor cell differentiation. The IPSCs differentiated into neural progenitors stained positive with Neurofluor CDr3 (FIG. 3B ). - Next, FA2 cells were transiently transfected with the plasmid containing the FXN expression construct and FXN protein levels were analyzed by Western Blot and the Li-COR Odyssey Imaging system. FA2 transiently transfected cells showing dose dependent increases of FXN (
FIG. 4 ). - Lastly, an aconitase activity assay was used to assess mitochondrial health in FA2 cells. Aconitase is a robust indicator of mitochondrial health. Moreover, in FXN deficient environments aconitase becomes susceptible to ROS attack. FA2 cells were transiently transfected with the plasmid containing the FXN expression construct. Aconitase activity was higher in FA2 cells transfected with the plasmid than in FA2 cells not transfected with the plasmid (
FIGS. 5A and 5B ). - These results show that correction of FXN expression in-vitro increased aconitase activity. Aconitase activity increased proportionally to FXN in a dose dependent manner. Western Blot analysis revealed that the expression vector generated transcriptionally and functionally active FXN. These results suggest that rAAV compositions of the present disclosure are useful, in some embodiments, for AAV-mediated gene therapy for FXN replacement in Friedreich's Ataxia.
- All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
- From the above description, one skilled in the art can easily ascertain the essential characteristics of the present disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications of the disclosure to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.
- While several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and/or structures for performing the function and/or obtaining the results and/or one or more of the advantages described herein, and each of such variations and/or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and/or configurations will depend upon the specific application or applications for which the inventive teachings is/are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and/or methods, if such features, systems, articles, materials, kits, and/or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.
- All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.
- All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.
- The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”
- The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.
- As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
- It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
- In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03. It should be appreciated that embodiments described in this document using an open-ended transitional phrase (e.g., “comprising”) are also contemplated, in alternative embodiments, as “consisting of” and “consisting essentially of” the feature described by the open-ended transitional phrase. For example, if the disclosure describes “a composition comprising A and B”, the disclosure also contemplates the alternative embodiments “a composition consisting of A and B” and “a composition consisting essentially of A and B”.
Claims (18)
1. A nucleic acid comprising an expression construct comprising a human FXN 5′ untranslated region (FXN 5′ UTR), or a fragment thereof, and a human frataxin (FXN) coding sequence, wherein the expression construct is flanked on each side by an inverted terminal repeat sequence.
2. The nucleic acid of claim 1 , wherein the FXN 5′ UTR sequence is a human FXN promoter (hFXNPro) sequence or a fragment thereof.
3. The nucleic acid of claim 2 comprising two or more fragments of a hFXNPro sequence.
4. The nucleic acid of claim 2 , wherein the fragment is derived from SEQ ID NO: 8.
5. The nucleic acid of claim 1 , wherein the FXN 5′ UTR sequence comprises a CACC box.
6. The nucleic acid of claim 1 , wherein the expression construct comprises an intron.
7. A recombinant adeno-associated virus (rAAV) particle comprising the nucleic acid of claim 1 .
8. The rAAV particle of claim 7 , wherein the rAAV particle is an AAV9 particle.
9. A composition comprising a plurality of the rAAV particle of claim 7 .
10. The composition of claim 9 further comprising a pharmaceutically acceptable carrier.
11. A method of treating Friedreich's ataxia, the method comprising:
administering a therapeutically effective amount of the rAAV particle of claim 7 to a subject having Friedreich's ataxia.
12. The method of claim 11 , wherein the rAAV particle is administered via intravenous injection.
13. The method of claim 11 , wherein the rAAV particle is administered via intrathecal injection.
14. The method of claim 11 , wherein the rAAV particle is administered via intracisternal injection.
15. The method of claim 12 further comprising administering the rAAV particle or composition via intrathecal injection.
16. The method of claim 12 further comprising administering the rAAV particle or composition via intracisternal injection.
17. The method of claim 15 , wherein the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intrathecal injection is 1:10.
18. The method of claim 16 , wherein the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intracisternal injection is 1:10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/365,845 US20210322571A1 (en) | 2015-04-24 | 2021-07-01 | Aav vector for treatment of friedreich's ataxia |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562152780P | 2015-04-24 | 2015-04-24 | |
PCT/US2016/029084 WO2016172659A1 (en) | 2015-04-24 | 2016-04-23 | Aav vector for treatment of friedreich's ataxia |
US201715568961A | 2017-10-24 | 2017-10-24 | |
US16/745,962 US20200138975A1 (en) | 2015-04-24 | 2020-01-17 | Aav vector for treatment of friedreich's ataxia |
US17/365,845 US20210322571A1 (en) | 2015-04-24 | 2021-07-01 | Aav vector for treatment of friedreich's ataxia |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/745,962 Continuation US20200138975A1 (en) | 2015-04-24 | 2020-01-17 | Aav vector for treatment of friedreich's ataxia |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210322571A1 true US20210322571A1 (en) | 2021-10-21 |
Family
ID=57143595
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/568,961 Active 2036-08-29 US10617770B2 (en) | 2015-04-24 | 2016-04-23 | AAV vector for treatment of Friedreich's ataxia |
US16/745,962 Abandoned US20200138975A1 (en) | 2015-04-24 | 2020-01-17 | Aav vector for treatment of friedreich's ataxia |
US17/365,845 Pending US20210322571A1 (en) | 2015-04-24 | 2021-07-01 | Aav vector for treatment of friedreich's ataxia |
US17/365,614 Active US11446395B2 (en) | 2015-04-24 | 2021-07-01 | AAV vector for treatment of Friedreich's ataxia |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/568,961 Active 2036-08-29 US10617770B2 (en) | 2015-04-24 | 2016-04-23 | AAV vector for treatment of Friedreich's ataxia |
US16/745,962 Abandoned US20200138975A1 (en) | 2015-04-24 | 2020-01-17 | Aav vector for treatment of friedreich's ataxia |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/365,614 Active US11446395B2 (en) | 2015-04-24 | 2021-07-01 | AAV vector for treatment of Friedreich's ataxia |
Country Status (3)
Country | Link |
---|---|
US (4) | US10617770B2 (en) |
EP (1) | EP3286321A4 (en) |
WO (1) | WO2016172659A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11446395B2 (en) | 2015-04-24 | 2022-09-20 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3632923A1 (en) * | 2015-01-16 | 2020-04-08 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
CA3002406A1 (en) * | 2015-10-29 | 2017-05-04 | Voyager Therapeutics, Inc. | Delivery of central nervous system targeting polynucleotides |
US12011488B2 (en) | 2016-03-23 | 2024-06-18 | The Regents Of The University Of California | Methods of treating mitochondrial disorders |
CA3018729A1 (en) | 2016-03-23 | 2017-09-28 | The Regents Of The University Of California | Methods of treating mitochondrial disorders |
US11564997B2 (en) * | 2016-06-29 | 2023-01-31 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
MX2019005235A (en) | 2016-11-09 | 2019-12-05 | Intrexon Corp | Frataxin expression constructs. |
EP3662060A2 (en) * | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
US11459363B2 (en) | 2019-07-29 | 2022-10-04 | The Trustees Of Indiana University | Materials and methods for treating Friedreich's Ataxia |
EP4028027A4 (en) * | 2019-09-13 | 2023-11-01 | Lacerta Therapeutics, Inc | Compositions and methods for treatment of friedreich's ataxia |
EP4065984A1 (en) | 2019-11-25 | 2022-10-05 | Larimar Therapeutics, Inc. | Methods for quantifying frataxin activity |
EP4142768A1 (en) | 2020-04-30 | 2023-03-08 | Larimar Therapeutics, Inc. | Methods for treating myelin associated diseases and mitochondria associated diseases |
CA3207161A1 (en) * | 2021-01-04 | 2022-07-07 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treatment of friedreich's ataxia |
US20240050521A1 (en) * | 2021-01-11 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Compositions for treating friedreich's ataxia |
WO2024097772A1 (en) * | 2022-11-01 | 2024-05-10 | Lacerta Therapeutics, Inc. | Compositions and methods for treatment of friedreich's ataxia |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020128183A1 (en) * | 2000-11-01 | 2002-09-12 | Broyles Robert H. | Gene regulation therapy involving ferritin |
US7098025B1 (en) * | 1997-07-25 | 2006-08-29 | Ligand Pharmaceuticals Incorporated | Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor |
US20150182637A1 (en) * | 2012-06-21 | 2015-07-02 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
WO2016115503A1 (en) * | 2015-01-16 | 2016-07-21 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
US10617770B2 (en) * | 2015-04-24 | 2020-04-14 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005080573A1 (en) | 2004-02-20 | 2005-09-01 | Universite De Montreal | Recombinant viral vectors to promote neuronal cell survival and uses thereof |
US20070161031A1 (en) * | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
WO2014095922A1 (en) * | 2012-12-17 | 2014-06-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of diagnosing or prognosing, or treating friedreich ataxia |
US9066966B2 (en) * | 2013-02-01 | 2015-06-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia |
RU2743792C2 (en) * | 2015-11-05 | 2021-02-26 | Бамбу Терапьютикс, Инк. | Modified freedreich ataxy genes and vectors for gene therapy |
-
2016
- 2016-04-23 WO PCT/US2016/029084 patent/WO2016172659A1/en unknown
- 2016-04-23 EP EP16784053.7A patent/EP3286321A4/en active Pending
- 2016-04-23 US US15/568,961 patent/US10617770B2/en active Active
-
2020
- 2020-01-17 US US16/745,962 patent/US20200138975A1/en not_active Abandoned
-
2021
- 2021-07-01 US US17/365,845 patent/US20210322571A1/en active Pending
- 2021-07-01 US US17/365,614 patent/US11446395B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098025B1 (en) * | 1997-07-25 | 2006-08-29 | Ligand Pharmaceuticals Incorporated | Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor |
US20020128183A1 (en) * | 2000-11-01 | 2002-09-12 | Broyles Robert H. | Gene regulation therapy involving ferritin |
US20150182637A1 (en) * | 2012-06-21 | 2015-07-02 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
WO2016115503A1 (en) * | 2015-01-16 | 2016-07-21 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
US10617770B2 (en) * | 2015-04-24 | 2020-04-14 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
US11446395B2 (en) * | 2015-04-24 | 2022-09-20 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
Non-Patent Citations (9)
Title |
---|
Dierks et al, Three regions upstream from the Cap site are required for efficient and accurate transcription of the rabbit beta-globin gene in mouse 3T6 cells, Cell 32: 695-706, 1983 * |
Fu et al, Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice, Gene Therapy 14: 1065-1077, 2007 * |
GenBank NG_008845.2, human frataxin gene; July 2, 2013 * |
Gomez-Sebastian et al, Infectious Delivery and Expression of a 135 kb Human FRDA Genomic DNA Locus Complements Friedreich’s Ataxia Deficiency in Human Cells, Molecular Therapy 15(2): 248-254, 2007 * |
Muenzer et al, Mol. Ther.16(Suppl 1): S45, 2008 * |
Oehmig et al, Update on Herpesvirus Amplicon Vectors, Molecular Therapy 10(4): 630-643, 2004 * |
Pook et al, Rescue of the Friedreich’s ataxia knockout mouse by human YAC transgenesis, Neurogenetics 3: 185-193, 2001 * |
Samaranch et al, Human Gene Therapy 23:382-389, 2012 * |
Schuster et al, Frontiers in Neuroanatomy 8(42): 1-14, June 10, 2014 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11446395B2 (en) | 2015-04-24 | 2022-09-20 | University Of Florida Research Foundation, Incorporated | AAV vector for treatment of Friedreich's ataxia |
Also Published As
Publication number | Publication date |
---|---|
US20210330815A1 (en) | 2021-10-28 |
US20180117178A1 (en) | 2018-05-03 |
EP3286321A4 (en) | 2018-10-17 |
EP3286321A1 (en) | 2018-02-28 |
US10617770B2 (en) | 2020-04-14 |
WO2016172659A1 (en) | 2016-10-27 |
US20200138975A1 (en) | 2020-05-07 |
US11446395B2 (en) | 2022-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11446395B2 (en) | AAV vector for treatment of Friedreich's ataxia | |
US10793861B2 (en) | Products and methods for treatment of familial amyotrophic lateral sclerosis | |
AU2021261838A1 (en) | Gene therapy for juvenile batten disease | |
KR20200018455A (en) | AADC Polynucleotides for the Treatment of Parkinson's Disease | |
KR20210068068A (en) | Prataxin expression constructs with engineered promoters and methods of use thereof | |
KR20210019996A (en) | Composition and method for the treatment of Parkinson's disease | |
TW202132570A (en) | Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders | |
TW202142692A (en) | Methods and systems for producing aav particles | |
CN112225793A (en) | Lysosome targeting peptide, fusion protein thereof, adeno-associated virus vector carrying fusion protein coding sequence and application thereof | |
TW202221125A (en) | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency | |
CN108137664B (en) | AAV-EPO for treatment of companion animals | |
WO2020010491A1 (en) | Nucleic acid for encoding human nadh dehydrogenase subunit 4 protein and application thereof | |
AU2023241362A1 (en) | Chimeric opsin GPCR proteins | |
KR102070763B1 (en) | Dopaminergic neuron specific expression control system | |
CN114127296A (en) | UBE3A gene and expression cassette and application thereof | |
CN112980819A (en) | Construction method and application of retinitis pigmentosa animal model | |
WO2020000641A1 (en) | Nucleic acid for coding human nadh dehydrogenase sigmasubunit protein and application thereof | |
CN112831524B (en) | Artificially modified recombinant adenovirus vector, virus packaged by same and application thereof | |
TWI813851B (en) | Frataxin expression constructs having engineered promoters and methods of use thereof | |
CN110423776B (en) | Vector for expressing recombinant blood coagulation factor FIX and construction method and application thereof | |
TW202302858A (en) | Insulin gene therapy to treat diabetes | |
TW202338095A (en) | Aav particles comprising a liver-tropic capsid protein and acid alpha-glucosidase (gaa) and their use to treat pompe disease | |
TW202227634A (en) | Systemic delivery of adeno-associated virus vector expressing g-sarcoglycan and the treatment of muscular dystrophy | |
TW202330929A (en) | Aav particles comprising a liver-tropic capsid protein and alpha-galactosidase and their use to treat fabry disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CORTI, MANUELA;BYRNE, BARRY JOHN;REEL/FRAME:057652/0968 Effective date: 20160518 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |